<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408437</article-id><article-id pub-id-type="pmc">PMC12101772</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0322720</article-id><article-id pub-id-type="publisher-id">PONE-D-25-03633</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Gastrointestinal Tumors</subject><subj-group><subject>Pancreatic Cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Cancer Detection and Diagnosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Detection and Diagnosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>RNA</subject><subj-group><subject>Non-coding RNA</subject><subj-group><subject>Natural antisense transcripts</subject><subj-group><subject>MicroRNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>Gene regulation</subject><subj-group><subject>MicroRNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Serum Proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Immunologic Techniques</subject><subj-group><subject>Immunoassays</subject><subj-group><subject>Enzyme-Linked Immunoassays</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject><subj-group><subject>Circulating tumor DNA</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Cancer detection and diagnosis</subject><subj-group><subject>Circulating tumor DNA</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer detection and diagnosis</subject><subj-group><subject>Circulating tumor DNA</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Science Policy</subject><subj-group><subject>Research Integrity</subject><subj-group><subject>Publication Ethics</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The role of novel biomarkers in the early diagnosis of pancreatic cancer: A systematic review and meta-analysis</article-title><alt-title alt-title-type="running-head">The role of novel biomarkers in the early diagnosis of pancreatic cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5995-8200</contrib-id><name><surname>Zheng</surname><given-names>Zeyi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Ziyu</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Fei</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0006-7652-0450</contrib-id><name><surname>Song</surname><given-names>Yani</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>School of Traditional Chinese Medicine, Inner Mongolia Medical University, Hohhot, China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>School of Basic Medicine, Inner Mongolia Medical University, Hohhot, China</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Cardiovascular Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>School of Water Resources and Hydropower Engineering, Wuhan University, Wuhan, Hubei, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Ren</surname><given-names>Shuai</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Affiliated Hospital of Nanjing University of Chinese Medicine: Jiangsu Province Academy of Traditional Chinese Medicine, CHINA</addr-line>
</aff><author-notes><corresp id="cor001">* E-mail: <email>ze96yi@163.com</email></corresp><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0322720</elocation-id><history><date date-type="received"><day>23</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Zheng et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zheng et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0322720.pdf">
</self-uri><abstract><sec><title>Background</title><p>Early detection of pancreatic cancer is essential for improving survival rates. However, noninvasive diagnostic methods are lacking. Novel biomarkers, detectable through liquid biopsy, such as circulating tumor DNA (ctDNA), microRNAs (miRNAs), protein markers, and metabolites, hold promise for early diagnosis.</p></sec><sec><title>Methods</title><p>A systematic search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted for studies published from January 2014 to May 2024. Studies were included if they evaluated novel biomarkers for early pancreatic cancer detection, reported diagnostic performance metrics (sensitivity, specificity), and had a QUADAS-2 score of &#x02265;3. Data on study characteristics, patient demographics, biomarker types, and diagnostic performance were extracted following PRISMA guidelines. A bivariate random-effects model was used to calculate pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). The area under the summary receiver operating characteristic (SROC) curve assessed overall diagnostic accuracy. The primary outcome was the diagnostic accuracy (sensitivity and specificity) of novel biomarkers in detecting early-stage pancreatic cancer.</p></sec><sec><title>Results</title><p>A total of 43 studies involving 19,326 participants were included, with 2,749 patients having stage I or II pancreatic cancer. The pooled sensitivities and specificities were as follows:.</p><p>miRNA Biomarkers: Sensitivity 0.88 (95% CI 0.79-0.93), Specificity 0.91 (95% CI 0.82-0.95), DOR 72.68 (95% CI 26.64-198.24), AUC 0.95.</p><p>Protein Biomarkers: Sensitivity 0.79 (95% CI 0.70-0.86), Specificity 0.88 (95% CI 0.82-0.93), DOR 27.74 (95% CI 14.32-53.76), AUC 0.90.</p><p>Metabolite Biomarkers: Sensitivity 0.84 (95% CI 0.73-0.92), Specificity 0.85 (95% CI 0.81-0.88), DOR 31.76 (95% CI 12.38-81.48), AUC 0.90.</p><p>ctDNA Biomarkers: Sensitivity 0.65 (95% CI 0.48-0.81), Specificity 0.94 (95% CI 0.88-0.97), DOR 27.73 (95% CI 12.91-59.55), AUC 0.92.</p><p>Subgroup analyses showed combining biomarkers with CA19&#x02013;9 improved diagnostic accuracy. Sensitivity analyses confirmed the robustness of the findings.</p></sec><sec><title>Conclusions</title><p>Novel biomarkers, particularly miRNAs and protein markers, demonstrate high diagnostic accuracy for early pancreatic cancer detection and have potential for clinical application in improving early diagnosis and patient outcomes.</p></sec><sec><title>Systematic review registration</title><p><ext-link xlink:href="https://www.crd.york.ac.uk/prospero/" ext-link-type="uri">https://www.crd.york.ac.uk/prospero/</ext-link>, Identifier: PROSPERO (CRD42024553633).</p></sec></abstract><funding-group><funding-statement>The author(s) received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="9"/><table-count count="3"/><page-count count="26"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its <xref rid="sec022" ref-type="sec">Supporting Information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its <xref rid="sec022" ref-type="sec">Supporting Information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Pancreatic cancer is among the most lethal malignancies, exhibiting the lowest survival rates across all cancer types [<xref rid="pone.0322720.ref001" ref-type="bibr">1</xref>]. It is projected to become the second leading cause of cancer-related deaths by 2030 [<xref rid="pone.0322720.ref002" ref-type="bibr">2</xref>]. This dismal mortality rate is primarily attributable to late-stage diagnoses, at which point curative treatments are often unfeasible. Early-stage surgical resection remains the principal potentially curative intervention for pancreatic cancer [<xref rid="pone.0322720.ref003" ref-type="bibr">3</xref>]. However, early-stage disease is frequently asymptomatic or presents with nonspecific symptoms such as fatigue, indigestion, and changes in bowel habits [<xref rid="pone.0322720.ref004" ref-type="bibr">4</xref>], complicating early detection efforts. One of the greatest challenges in the management of PDAC is achieving early detection in high-risk individuals and accurately diagnosing patients who present with suspected symptoms [<xref rid="pone.0322720.ref005" ref-type="bibr">5</xref>]. Consequently, over two-thirds of patients present with regional or distant metastases at diagnosis [<xref rid="pone.0322720.ref006" ref-type="bibr">6</xref>]. The five-year survival rate for patients diagnosed with localized pancreatic cancer is significantly higher than for those with advanced disease stages [<xref rid="pone.0322720.ref007" ref-type="bibr">7</xref>]. Therefore, early detection and diagnosis are critical for improving survival outcomes in pancreatic cancer.</p><p>Currently, effective methods for early detection are lacking. Imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasound-guided fine-needle aspiration are limited by cost, invasiveness, and suboptimal sensitivity and specificity, especially in early-stage disease [<xref rid="pone.0322720.ref008" ref-type="bibr">8</xref>]. The most widely used noninvasive biomarker, serum carbohydrate antigen 19&#x02013;9 (CA19&#x02013;9), has limited sensitivity and specificity for early pancreatic cancer detection [<xref rid="pone.0322720.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0322720.ref010" ref-type="bibr">10</xref>]. Elevated CA19&#x02013;9 levels can occur in benign conditions like pancreatitis and other malignancies, leading to false positives [<xref rid="pone.0322720.ref011" ref-type="bibr">11</xref>]. Additionally, approximately 5% to 10% of the population are Lewis antigen-negative and do not produce CA19&#x02013;9, resulting in false negatives [<xref rid="pone.0322720.ref012" ref-type="bibr">12</xref>]. Research and application of novel biomarkers for the early detection of potentially curable pancreatic cancer remain in their infancy. There is an urgent need for accurate, cost-effective, and efficient noninvasive detection methods capable of diagnosing pancreatic cancer at a resectable stage, which is critical for improving the five-year survival rate of patients with PDAC [<xref rid="pone.0322720.ref013" ref-type="bibr">13</xref>].</p><p>Recent advancements have identified novel biomarkers detectable through liquid biopsies, such as circulating tumor DNA (ctDNA), microRNAs (miRNAs), specific protein markers, and metabolite biomarkers [<xref rid="pone.0322720.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0322720.ref015" ref-type="bibr">15</xref>], which show promise in the early diagnosis of pancreatic cancer. These biomarkers offer the potential for noninvasive, sensitive, and specific detection methods. This meta-analysis aims to evaluate the sensitivity and specificity of various novel biomarkers in the early diagnosis of pancreatic cancer, compare their diagnostic performance, and identify the most promising biomarkers for clinical application.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Protocol and registration</title><p>We conducted this systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [<xref rid="pone.0322720.ref016" ref-type="bibr">16</xref>]. The study protocol was registered with PROSPERO (registration number CRD42024553633).</p></sec><sec id="sec004"><title>Eligibility criteria</title><p>We included studies that met the following criteria:</p><list list-type="order"><list-item><p>Study Design: Cohort studies, case-control studies, and diagnostic test accuracy studies.</p></list-item><list-item><p>Participants: Patients suspected of or diagnosed with pancreatic cancer.</p></list-item><list-item><p>Biomarkers: Evaluations of novel biomarkers such as ctDNA, miRNAs, or specific protein markers for early diagnosis.</p></list-item><list-item><p>Outcomes: Reports on diagnostic performance metrics, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).</p></list-item><list-item><p>Quality Assessment: Studies assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool were included only if they had a rating of &#x0201c;high risk&#x0201d; in at most one domain of bias [<xref rid="pone.0322720.ref017" ref-type="bibr">17</xref>].</p></list-item></list><p>Exclusion criteria were:</p><list list-type="order"><list-item><p>Non-human studies.</p></list-item><list-item><p>Studies lacking complete diagnostic performance data.</p></list-item><list-item><p>Duplicate publications.</p></list-item><list-item><p>Studies with excessive heterogeneity in design, patient population, or biomarker detection methods, as identified by QUADAS-2 evaluation.</p></list-item><list-item><p>Small-scale studies with fewer than 30 participants or conducted exclusively in specific regions or healthcare systems.</p></list-item></list><p>Exclusion of Pancreatic Cancer</p><p>In the included studies, patients with confirmed pancreatic cancer were excluded based on several criteria. First, any study focusing on patients already diagnosed with pancreatic cancer was excluded, with the diagnosis confirmed through clinical evaluation and medical records. Second, studies that included patients with a history of pancreatic cancer or evidence of malignancy, as determined by clinical assessment, imaging tests (such as CT or MRI), or biopsy, were also excluded. Additionally, studies specifically targeting early-stage pancreatic cancer detection (e.g., stage I and II) excluded patients with advanced-stage cancer (III or IV), which was determined through clinical staging, imaging, and histopathological examination. These procedures were implemented to ensure that all included studies focused on identifying biomarkers for the early detection of pancreatic cancer, while excluding patients with a confirmed diagnosis of the disease.</p></sec><sec id="sec005"><title>Search strategy</title><p>We performed a comprehensive literature search for studies published from January 2014 to May 2024. The search was conducted on June 1, 2024. Databases searched included PubMed, Embase, Web of Science, and the Cochrane Library. We combined MeSH terms and free-text keywords related to &#x0201c;pancreatic cancer,&#x0201d; &#x0201c;early diagnosis,&#x0201d; and &#x0201c;novel biomarkers&#x0201d; using Boolean operators (AND, OR).The specific search terms were:</p><list list-type="simple"><list-item><p>Population: &#x0201c;pancreatic cancer&#x0201d; OR &#x0201c;pancreatic carcinoma&#x0201d;</p></list-item><list-item><p>Intervention: &#x0201c;biomarker&#x0201d; OR &#x0201c;circulating tumor DNA&#x0201d; OR &#x0201c;ctDNA&#x0201d; OR &#x0201c;microRNA&#x0201d; OR &#x0201c;miRNA&#x0201d; OR &#x0201c;protein marker&#x0201d;</p></list-item><list-item><p>Outcome: &#x0201c;early diagnosis&#x0201d; OR &#x0201c;early detection&#x0201d; AND &#x0201c;diagnostic accuracy&#x0201d; OR &#x0201c;sensitivity&#x0201d; OR &#x0201c;specificity&#x0201d;</p></list-item></list><p>We also screened reference lists of relevant articles to identify additional studies.</p><p>The specific search strategy is detailed in the attached table (<xref rid="pone.0322720.s001" ref-type="supplementary-material">S1 Table</xref>).</p></sec><sec id="sec006"><title>Study selection</title><p>The search strategy results were stored and managed using the Endnote software. Two independent reviewers screened the titles and abstracts of all retrieved articles. Full-text articles were obtained for studies meeting the inclusion criteria or when eligibility was uncertain. Discrepancies were resolved through discussion or consultation with a third reviewer.</p></sec><sec id="sec007"><title>Data extraction</title><p>Two reviewers independently extracted data using a standardized form, including:</p><list list-type="simple"><list-item><p>Study Characteristics: Author, publication year, country, study design, and sample size.</p></list-item><list-item><p>Patient Characteristics: Age, sex, and disease stage.</p></list-item><list-item><p>Biomarker Details: Specific biomarkers evaluated and detection methods used (e.g., PCR, NGS).</p></list-item><list-item><p>Diagnostic Performance Metrics: Sensitivity, specificity, PPV, NPV, and 95% confidence intervals.</p></list-item><list-item><p>Quality Assessment: QUADAS-2 scores for patient selection, index test, reference standard, and flow and timing.</p></list-item></list><p>Any discrepancies were resolved by consensus or involving a third reviewer.</p><p>Missing data were managed by initially contacting the corresponding authors of the original studies to obtain any unavailable or unclear information. In the absence of a response, missing values were estimated from figures or derived through appropriate statistical conversions based on the available data. Studies with substantial missing data that could not be reliably imputed were excluded from the meta-analysis.</p></sec><sec id="sec008"><title>Quality assessment</title><p>We assessed the methodological quality of the included studies using the QUADAS-2 tool, which evaluates the risk of bias across four domains (patient selection, index test, reference standard, flow and timing) and applicability concerns across three domains (patient selection, index test, reference standard). Two reviewers independently rated the risk of bias and applicability concerns for each domain as &#x0201c;low,&#x0201d; &#x0201c;high,&#x0201d; or &#x0201c;unclear.&#x0201d; Studies were included if at most one bias domain was rated as &#x0201c;high risk&#x0201d; (out of four bias domains). Applicability concerns were documented but did not influence the inclusion decision, as they pertain to generalizability rather than internal validity. Disagreements between reviewers were resolved through discussion or consultation with a third reviewer.</p></sec><sec id="sec009"><title>Statistical analysis</title><p>We used Stata version 16 for statistical analyses. A bivariate random-effects model calculated pooled estimates of sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) with 95% confidence intervals. We constructed summary receiver operating characteristic (SROC) curves and calculated the area under the curve (AUC) to evaluate overall diagnostic accuracy.</p><p>Heterogeneity among studies was assessed using Cochran&#x02019;s Q test and the I&#x000b2; statistic. An I&#x000b2; value over 50% indicated substantial heterogeneity [<xref rid="pone.0322720.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0322720.ref019" ref-type="bibr">19</xref>]. We explored potential sources of heterogeneity through subgroup analyses based on biomarker type, sample type (blood, urine), and detection methods (e.g., PCR, NGS).</p><p>Sensitivity analyses excluded studies with a high risk of bias to assess the robustness of pooled estimates. We evaluated publication bias using funnel plots and Deeks&#x02019; funnel plot asymmetry test.</p></sec><sec id="sec010"><title>Results reporting</title><p>We reported results following PRISMA guidelines. A flow diagram illustrated the study selection process. Tables summarized the characteristics of included studies and quality assessment outcomes. Forest plots presented pooled diagnostic performance metrics. We documented assessments of heterogeneity and publication bias and reported findings from subgroup and sensitivity analyses.</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>Study selection and characteristics</title><p>Our search yielded 1,742 studies, with 502 duplicates removed. After screening titles and abstracts, we selected 222 studies for full-text evaluation. Of these, 178 were excluded for reasons such as not being diagnostic tests, unclear cancer stage definition, lacking specific biomarkers, incomplete diagnostic data, and sample sizes of fewer than 30 participants. An additional two studies were excluded due to insufficient numbers for meta-analysis. Ultimately, 42 studies met the eligibility criteria (<xref rid="pone.0322720.g001" ref-type="fig">Fig 1</xref>).</p><fig position="float" id="pone.0322720.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.g001</object-id><label>Fig 1</label><caption><title> PRISMA flowchart illustrating the process of screening and selection of studies.</title></caption><graphic xlink:href="pone.0322720.g001" position="float"/></fig><p><xref rid="pone.0322720.t001" ref-type="table">Tables 1</xref> and <xref rid="pone.0322720.t002" ref-type="table">2</xref> summarize the included studies, published between 2014 and 2024, involving 19,326 participants. Among them, 2,749 patients had stage I or II pancreatic cancer. All studies used the internationally accepted TNM staging system. Four studies included only stage I patients, three included only stage II patients, and the remaining 36 studies included both stages. The control groups consisted of 16,577 individuals, including patients with chronic pancreatitis, benign pancreatic diseases, and healthy volunteers. Specifically, 28 studies exclusively used healthy volunteers as controls, whereas 15 studies included both healthy volunteers and patients with chronic pancreatitis or benign pancreatic diseases as controls (<xref rid="pone.0322720.t001" ref-type="table">Tables 1</xref> and <xref rid="pone.0322720.t002" ref-type="table">2</xref>).</p><table-wrap position="float" id="pone.0322720.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.t001</object-id><label>Table 1</label><caption><title>Baseline Demographic and Geographic Characteristics of Study Populations.</title></caption><alternatives><graphic xlink:href="pone.0322720.t001" id="pone.0322720.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">author</th><th align="left" rowspan="1" colspan="1">year</th><th align="left" rowspan="1" colspan="1">age</th><th align="left" rowspan="1" colspan="1">Gender, men(%)</th><th align="left" rowspan="1" colspan="1">region</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Fujimoto</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Healthy 55 (34&#x02013;88)<break/>Benign pancreatic disease 69.5 (54&#x02013;80)<break/>Pancreatic cancer 71 (51&#x02013;92)</td><td align="left" rowspan="1" colspan="1">Healthy 54<break/>Benign pancreatic disease 83<break/>Pancreatic cancer 53</td><td align="left" rowspan="1" colspan="1">Japan</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Majumder</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 72.3 (66.0-78.0)<break/>Healthy 69.9 (60.8-75.4)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 66<break/>Healthy 66</td><td align="left" rowspan="1" colspan="1">USA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wu</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 63.1 (35&#x02013;80)<break/>Healthy 51.1 (18&#x02013;79)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 60.9<break/>Healthy 40.5</td><td align="left" rowspan="1" colspan="1">China</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Bauden</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 69 (46&#x02013;78)<break/>Healthy 58 (48&#x02013;70)<break/>Benign disease 72 (58&#x02013;77)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">Sweden</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Henriksen</bold>
</td><td align="left" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 66 (45&#x02013;85)<break/>Control groups 58 (22&#x02013;87)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 60<break/>Control groups 63.71</td><td align="left" rowspan="1" colspan="1">Denmark</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Eissa</bold>
</td><td align="left" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 60.1 (29&#x02013;83)<break/>Control 65.5 (21&#x02013;96)<break/>Pancreatitis 46.6 (29&#x02013;70)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 67<break/>Control 43<break/>Pancreatitis 50</td><td align="left" rowspan="1" colspan="1">USA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cohen</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 66.9&#x02009;&#x000b1;&#x02009;10.5</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 54.8</td><td align="left" rowspan="1" colspan="1">USA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Debernardi</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Healthy 60.7<break/>Pancreatic cancer 64.1</td><td align="left" rowspan="1" colspan="1">Healthy 46.2<break/>Pancreatic cancer 54.3</td><td align="left" rowspan="1" colspan="1">UK</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Masterson</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 65 (18&#x02013;90)<break/>Control 56 (39&#x02013;80)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 57.3<break/>Control 48.3</td><td align="left" rowspan="1" colspan="1">USA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yu</bold>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 62.26&#x02009;&#x000b1;&#x02009;9.51<break/>Control 59.98&#x02009;&#x000b1;&#x02009;7.14</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 36.6<break/>Control 50</td><td align="left" rowspan="1" colspan="1">China</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nakamura</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 67.6 (&#x000b1;7.9)<break/>Control 41.0 (&#x000b1;9.1)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 15 (45.5%)<break/>Control 41 (66.1%)</td><td align="left" rowspan="1" colspan="1">USA/Japan/Korea</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Huang</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 60<break/>Healthy 45<break/>Pancreatitis 55<break/>pancreatic cystic neoplasms 53</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 56.6<break/>Healthy 54.5<break/>Pancreatitis 62.2<break/>pancreatic cystic neoplasms 32.1</td><td align="left" rowspan="1" colspan="1">China</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Schultz</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 67<break/>Healthy 51<break/>Pancreatitis 55</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 58.4<break/>Healthy 47.4<break/>Pancreatitis 64</td><td align="left" rowspan="1" colspan="1">Denmark</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Ganepola</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 68 (62&#x02013;79)<break/>Healthy 46 (42&#x02013;49)<break/>High risk 48 (46&#x02013;50)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 54<break/>Healthy 54<break/>High risk 27</td><td align="left" rowspan="1" colspan="1">USA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wolrab</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Healthy 65&#x02009;&#x000b1;&#x02009;4<break/>Pancreatic cancer 67&#x02009;&#x000b1;&#x02009;4</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">Czech Republic</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Fukutake</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 66.7&#x02009;&#x000b1;&#x02009;9.1<break/>Healthy 52.2&#x02009;&#x000b1;&#x02009;10.0<break/>Pancreatitis 61.5&#x02009;&#x000b1;&#x02009;13.7</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 62.9<break/>Healthy 63.8<break/>Pancreatitis 57.1</td><td align="left" rowspan="1" colspan="1">Japan</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Xie</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 67.9 (44.2-85.7)<break/>Control 67.8 (44.1-84.3)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 49<break/>Control 49</td><td align="left" rowspan="1" colspan="1">USA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Xie</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 64.3 (40.5-79.1)<break/>Control 64.4 (41.2-79.2)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 50<break/>Control 50</td><td align="left" rowspan="1" colspan="1">China</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Zhang</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 57.1 (35&#x02013;78)<break/>Healthy 57.8 (34&#x02013;81)<break/>Pancreatitis 55.6 (35&#x02013;79)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 51.6<break/>Healthy 55.1<break/>Pancreatitis 52.5</td><td align="left" rowspan="1" colspan="1">China</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Mayerle</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Healthy 69(61&#x02013;74)<break/>Pancreatic cancer 68(55&#x02013;74)</td><td align="left" rowspan="1" colspan="1">Healthy 52.5<break/>Pancreatic cancer 46.8</td><td align="left" rowspan="1" colspan="1">Germany</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hirata</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Healthy 65(45&#x02013;86)<break/>Pancreatic cancer 69(63&#x02013;85)</td><td align="left" rowspan="1" colspan="1">Healthy 46.6<break/>Pancreatic cancer 63.0</td><td align="left" rowspan="1" colspan="1">Japan</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yamada</bold>
</td><td align="left" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">Healthy 56.2 (40&#x02013;75)<break/>Pancreatic cancer 69.7 (25&#x02013;96)</td><td align="left" rowspan="1" colspan="1">Healthy 46.5<break/>Pancreatic cancer 38.2</td><td align="left" rowspan="1" colspan="1">Japan</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wang</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">Healthy 102(&#x02264;45) 153(46&#x02013;55) 121(56&#x02013;65) 124(&#x0003e;65)<break/>Pancreatic cancer 111(&#x02264;45) 215(46&#x02013;55) 272(56&#x02013;65) 209(&#x0003e;65)</td><td align="left" rowspan="1" colspan="1">Healthy 57.4<break/>Pancreatic cancer 54.3</td><td align="left" rowspan="1" colspan="1">China</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Matsunaga</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Healthy 60(23&#x02013;81)<break/>Pancreatic cancer 70(39&#x02013;91)</td><td align="left" rowspan="1" colspan="1">Healthy 36.1<break/>Pancreatic cancer 63.8</td><td align="left" rowspan="1" colspan="1">USA/Japan</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Zhou</bold>
</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 83(&#x0003e;60) 73(&#x02264;60)<break/>Healthy 87(&#x0003e;60) 76(&#x02264;60)<break/>Pancreatitis 3(&#x0003e;60) 13(&#x02264;60)<break/>benign pancreatic tumor 4(&#x0003e;60) 16(&#x02264;60)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 59.6<break/>Healthy 58.3<break/>Pancreatitis 100<break/>benign pancreatic tumor 20</td><td align="left" rowspan="1" colspan="1">China</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Sato</bold>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 69.0 (21&#x02013;86)<break/>Control 52.0 (22&#x02013;89)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 69.5<break/>Control 52.1</td><td align="left" rowspan="1" colspan="1">Japan</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Mawaribuchi</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Healthy 50.7(22&#x02013;70)<break/>Pancreatic cancer 67.9(36&#x02013;92)</td><td align="left" rowspan="1" colspan="1">Healthy 76.8<break/>Pancreatic cancer 59.1</td><td align="left" rowspan="1" colspan="1">Japan</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nam</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Healthy 36.0 (18&#x02013;73)<break/>Early-stage Pancreatic cancer 65.0 (44&#x02013;86)</td><td align="left" rowspan="1" colspan="1">Healthy 54.1<break/>Early-stage Pancreatic cancer 65.8</td><td align="left" rowspan="1" colspan="1">Korea</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Han</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 61.7&#x02009;&#x000b1;&#x02009;10.8<break/>Healthy 59.1&#x02009;&#x000b1;&#x02009;11.0<break/>Pancreatitis 57.6&#x02009;&#x000b1;&#x02009;11.3<break/>benign pancreatic tumor 58.8&#x02009;&#x000b1;&#x02009;12.1</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 62.9<break/>Healthy 62.5<break/>Pancreatitis 84.6<break/>benign pancreatic tumor 66.7</td><td align="left" rowspan="1" colspan="1">China</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kashiro</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">Healthy 63.2 (50&#x02013;89)<break/>Pancreatic cancer 65.2 (38&#x02013;86)</td><td align="left" rowspan="1" colspan="1">Healthy 50.9<break/>Pancreatic cancer 56.6</td><td align="left" rowspan="1" colspan="1">Japan</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yu</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Healthy 70.7&#x02009;&#x000b1;&#x02009;12.3<break/>Pancreatic cancer 61.9&#x02009;&#x000b1;&#x02009;12.9</td><td align="left" rowspan="1" colspan="1">Healthy 55.6<break/>Pancreatic cancer 59.5</td><td align="left" rowspan="1" colspan="1">Sweden/Spain</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Mohamed</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Healthy 62 (46&#x02013;81)<break/>Pancreatic cancer 63 (47&#x02013;80)</td><td align="left" rowspan="1" colspan="1">Healthy 55<break/>Pancreatic cancer 64</td><td align="left" rowspan="1" colspan="1">Egypt</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Radon</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Healthy 55 (28&#x02013;87)<break/>Pancreatic cancer 68 (29&#x02013;94)</td><td align="left" rowspan="1" colspan="1">Healthy 52.9<break/>Pancreatic cancer 59.4</td><td align="left" rowspan="1" colspan="1">UK/Spain/USA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Li</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Healthy 61.6<break/>Pancreatic cancer 61.7</td><td align="left" rowspan="1" colspan="1">Healthy 58.8<break/>Pancreatic cancer 58.8</td><td align="left" rowspan="1" colspan="1">China</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lee. M</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 60.4&#x02009;&#x000b1;&#x02009;10.5<break/>Healthy 53.7&#x02009;&#x000b1;&#x02009;14.5<break/>Pancreatitis 48.3&#x02009;&#x000b1;&#x02009;14.0</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 57.1<break/>Healthy 72<break/>Pancreatitis 80</td><td align="left" rowspan="1" colspan="1">Korea</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Brand</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Median age (yr)<break/>Healthy 49<break/>Pancreatic cancer 70</td><td align="left" rowspan="1" colspan="1">Healthy 51<break/>Pancreatic cancer 58</td><td align="left" rowspan="1" colspan="1">USA/Sweden/Spain/Belgium/Finland</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Aronsson</bold>
</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Healthy 60 (56&#x02013;63)<break/>Pancreatic cancer 68 (64&#x02013;71)</td><td align="left" rowspan="1" colspan="1">Healthy 68<break/>Pancreatic cancer 49</td><td align="left" rowspan="1" colspan="1">Sweden</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wen</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">Healthy 57 (43, 71)<break/>Pancreatic cancer 64 (54.74)</td><td align="left" rowspan="1" colspan="1">Healthy 43.2<break/>Pancreatic cancer 63.4</td><td align="left" rowspan="1" colspan="1">China</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Haab</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 64.3 (40.5-79.1)<break/>Control 64.4 (41.2-79.2)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 50.6<break/>Control 41.6</td><td align="left" rowspan="1" colspan="1">USA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kim</bold>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">Healthy 57.5 (8.6)<break/>Pancreatic cancer 66.0 (9.5)</td><td align="left" rowspan="1" colspan="1">Healthy 60.7<break/>Pancreatic cancer 70</td><td align="left" rowspan="1" colspan="1">Korea</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lee. D</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Healthy 56.4&#x02009;&#x000b1;&#x02009;11.0<break/>Pancreatic cancer 63.1&#x02009;&#x000b1;&#x02009;9.9</td><td align="left" rowspan="1" colspan="1">Healthy 52.9<break/>Pancreatic cancer 60.8</td><td align="left" rowspan="1" colspan="1">Korea</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Firpo</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 69 (61&#x02013;74)<break/>Healthy 57 (51&#x02013;67)<break/>Pancreatitis 50 (39&#x02013;62)<break/>intraductal papillary mucinous neoplasm 67 (57&#x02013;73)</td><td align="left" rowspan="1" colspan="1">Pancreatic cancer 47<break/>Healthy 50<break/>Pancreatitis 53<break/>intraductal papillary mucinous neoplasm 39</td><td align="left" rowspan="1" colspan="1">USA/Italy</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Zhang</bold>
</td><td align="left" rowspan="1" colspan="1">2013</td><td align="left" rowspan="1" colspan="1">Healthy 53.74 (19&#x02013;85)<break/>Pancreatic cancer 54.36 (18&#x02013;85)</td><td align="left" rowspan="1" colspan="1">Healthy 51.9<break/>Pancreatic cancer 60.5</td><td align="left" rowspan="1" colspan="1">China</td></tr></tbody></table></alternatives></table-wrap><table-wrap position="float" id="pone.0322720.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.t002</object-id><label>Table 2</label><caption><title>Study Characteristics and Diagnostic Outcomes.</title></caption><alternatives><graphic xlink:href="pone.0322720.t002" id="pone.0322720.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">author</th><th align="left" rowspan="1" colspan="1">year</th><th align="left" rowspan="1" colspan="1">tp</th><th align="left" rowspan="1" colspan="1">fp</th><th align="left" rowspan="1" colspan="1">fn</th><th align="left" rowspan="1" colspan="1">tn</th><th align="left" rowspan="1" colspan="1">sample size</th><th align="left" rowspan="1" colspan="1">stage</th><th align="left" rowspan="1" colspan="1">control</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Fujimoto</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">Stage&#x02160;</td><td align="left" rowspan="1" colspan="1">NC<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Majumder</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wu</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">106</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Bauden</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">Stage&#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Henriksen</bold>
</td><td align="left" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">103</td><td align="left" rowspan="1" colspan="1">164</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Eissa</bold>
</td><td align="left" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">132</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cohen</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">155</td><td align="left" rowspan="1" colspan="1">181</td><td align="left" rowspan="1" colspan="1">403</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Debernardi</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">Stage&#x02160;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Masterson</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yu</bold>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">133</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nakamura</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Huang</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">98</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">271</td><td align="left" rowspan="1" colspan="1">455</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Schultz</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">279</td><td align="left" rowspan="1" colspan="1">417</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Ganepola</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">Stage&#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wolrab</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Fukutake</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">1554</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">6218</td><td align="left" rowspan="1" colspan="1">7856</td><td align="left" rowspan="1" colspan="1">Stage&#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Xie</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">166</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Xie</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">200</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Zhang</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">239</td><td align="left" rowspan="1" colspan="1">281</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Mayerle</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hirata</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">112</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yamada</bold>
</td><td align="left" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">Stage&#x02160;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wang</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">112</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">482</td><td align="left" rowspan="1" colspan="1">672</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Matsunaga</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;A</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Zhou</bold>
</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">271</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Sato</bold>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">395</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3766</td><td align="left" rowspan="1" colspan="1">4178</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Mawaribuchi</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">128</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;A</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nam</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">106</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">186</td><td align="left" rowspan="1" colspan="1">310</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Han</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">154</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kashiro</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">136</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yu</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Mohamed</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Radon</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Li</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">145</td><td align="left" rowspan="1" colspan="1">237</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lee. M</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Brand</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">214</td><td align="left" rowspan="1" colspan="1">272</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Aronsson</bold>
</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">Stage&#x02160;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wen</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">139</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Haab</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">122</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">118</td><td align="left" rowspan="1" colspan="1">295</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kim</bold>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">183</td><td align="left" rowspan="1" colspan="1">233</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lee. D</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">180</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">167</td><td align="left" rowspan="1" colspan="1">375</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Firpo</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">104</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">NC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Zhang</bold>
</td><td align="left" rowspan="1" colspan="1">2013</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">165</td><td align="left" rowspan="1" colspan="1">241</td><td align="left" rowspan="1" colspan="1">Stage&#x02160; and &#x02161;</td><td align="left" rowspan="1" colspan="1">HC</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>a NC: Non-cancer Control group (including pancreatitis, benign pancreatic diseases).</p></fn><fn id="t002fn002"><p>b HC: Healthy Control group.</p></fn></table-wrap-foot></table-wrap><p>Regarding biomarker types, seven studies investigated ctDNA [<xref rid="pone.0322720.ref020" ref-type="bibr">20</xref>&#x02013;<xref rid="pone.0322720.ref026" ref-type="bibr">26</xref>], seven focused on miRNAs [<xref rid="pone.0322720.ref027" ref-type="bibr">27</xref>&#x02013;<xref rid="pone.0322720.ref033" ref-type="bibr">33</xref>], and seven assessed metabolites [<xref rid="pone.0322720.ref034" ref-type="bibr">34</xref>&#x02013;<xref rid="pone.0322720.ref039" ref-type="bibr">39</xref>] (<xref rid="pone.0322720.t003" ref-type="table">Table 3</xref>). Most studies (n&#x02009;=&#x02009;27) evaluated more than one biomarker. Sixteen studies focused on a single biomarker. One metabolite study [<xref rid="pone.0322720.ref036" ref-type="bibr">36</xref>] reported on two independent cohorts from China and the United States, treated separately in our analysis. Additionally, 17 studies evaluated protein biomarkers [<xref rid="pone.0322720.ref040" ref-type="bibr">40</xref>&#x02013;<xref rid="pone.0322720.ref056" ref-type="bibr">56</xref>]. Five studies [<xref rid="pone.0322720.ref057" ref-type="bibr">57</xref>&#x02013;<xref rid="pone.0322720.ref061" ref-type="bibr">61</xref>] exclusively examined combining novel biomarkers with CA19&#x02013;9 and were included in subgroup analyses.</p><table-wrap position="float" id="pone.0322720.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.t003</object-id><label>Table 3</label><caption><title>Biomarker Types, Detection Methods, and Sample Types.</title></caption><alternatives><graphic xlink:href="pone.0322720.t003" id="pone.0322720.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">author</th><th align="left" rowspan="1" colspan="1">year</th><th align="left" rowspan="1" colspan="1">biomaker type</th><th align="left" rowspan="1" colspan="1">biomarker name</th><th align="left" rowspan="1" colspan="1">detection methods</th><th align="left" rowspan="1" colspan="1">specimens</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Fujimoto</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">ctDNA</td><td align="left" rowspan="1" colspan="1">Methylated RUNX3</td><td align="left" rowspan="1" colspan="1">CORD assay (Combined Restriction Digital PCR)</td><td align="left" rowspan="1" colspan="1">blood</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Majumder</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">ctDNA</td><td align="left" rowspan="1" colspan="1">Thirteen methylated DNA markers (GRIN2D, CD1D, ZNF781, FER1L4, RYR2, CLEC11A, AK055957, LRRC4, GH05J042948, HOXA1, PRKCB, SHISA9, and NTRK3)</td><td align="left" rowspan="1" colspan="1">plasma TELQAS (target enrichment with long probe quantitative amplified signal) assays</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wu</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">ctDNA</td><td align="left" rowspan="1" colspan="1">methylation signature of circulating tumour DNA</td><td align="left" rowspan="1" colspan="1">Reduced representation bisulfite sequencing(RRBS) and targeted methylation sequencing</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Bauden</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">ctDNA</td><td align="left" rowspan="1" colspan="1">5-methylcytosine</td><td align="left" rowspan="1" colspan="1">Nucleosomics, a novel ELISA method.</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Henriksen</bold>
</td><td align="left" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">ctDNA</td><td align="left" rowspan="1" colspan="1">Cell-free DNA promoter hypermethylation in plasma(BMP3, RASSF1A, BNC1, MESTv2, TFPI2, APC, SFRP1 and SFRP2)</td><td align="left" rowspan="1" colspan="1">methylation-specific PCR</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Eissa</bold>
</td><td align="left" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">ctDNA</td><td align="left" rowspan="1" colspan="1">promoter DNA methylation of the genes ADAMTS1 and BNC1</td><td align="left" rowspan="1" colspan="1">methylation on beads (MOB)</td><td align="left" rowspan="1" colspan="1">blood</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cohen</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">ctDNA</td><td align="left" rowspan="1" colspan="1">ctDNA</td><td align="left" rowspan="1" colspan="1">Safe-SeqS</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Debernardi</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">miRNA</td><td align="left" rowspan="1" colspan="1">miRNA biomarkers(miR-143, miR-223, miR-204, miR-30e)</td><td align="left" rowspan="1" colspan="1">RT-PCR</td><td align="left" rowspan="1" colspan="1">urinary</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Masterson</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">miRNA</td><td align="left" rowspan="1" colspan="1">microRNA-10b+microRNA-let7a</td><td align="left" rowspan="1" colspan="1">nanoplasmonic sensors</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yu</bold>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">miRNA</td><td align="left" rowspan="1" colspan="1">miRNA-25</td><td align="left" rowspan="1" colspan="1">RT-PCR</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nakamura</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">miRNA</td><td align="left" rowspan="1" colspan="1">5 cf-miRNAs (miR30c-5p, miR340-5p, miR335-5p, miR23b-3p and miR142-3p) and 8 exo-miRNA candidates (miR145-5p, miR200b-3p, miR429, miR1260b, miR145-3p, miR216b-5p, miR200a-3p and miR217-5p)</td><td align="left" rowspan="1" colspan="1">qRT-PCR</td><td align="left" rowspan="1" colspan="1">blood</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Huang</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">miRNA</td><td align="left" rowspan="1" colspan="1">miRNA Panel(hsa-miR-132-3p, hsa-miR-30c-5p, hsa-miR-24-3p, hsa-miR-23a-3p)</td><td align="left" rowspan="1" colspan="1">RT-PCR</td><td align="left" rowspan="1" colspan="1">Serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Schultz</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">miRNA</td><td align="left" rowspan="1" colspan="1">miR-26b, miR-34a, miR-122, miR-126*, miR-145, miR-150, miR-223, miR-505, miR-636, miR-885.5p</td><td align="left" rowspan="1" colspan="1">qPCR and TaqMan assays</td><td align="left" rowspan="1" colspan="1">blood</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Ganepola</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">miRNA</td><td align="left" rowspan="1" colspan="1">miR-642b-3p, miR-885-5p, miR-22-3p</td><td align="left" rowspan="1" colspan="1">RT-qPCR</td><td align="left" rowspan="1" colspan="1">blood</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wolrab</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Metabolite</td><td align="left" rowspan="1" colspan="1">serum lipids(sphingomyelins (SM), ceramides (Cer), phosphatidylcholines (PC), lysophosphatidylcholines (LPC))</td><td align="left" rowspan="1" colspan="1">UHPSFC/MS, shotgun MS and MALDI-MS</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Fukutake</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Metabolite</td><td align="left" rowspan="1" colspan="1">six plasma free amino acids: serine, asparagine, isoleucine, alanine, histidine, and tryptophan</td><td align="left" rowspan="1" colspan="1">HPLC-MS</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Xie</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Metabolite</td><td align="left" rowspan="1" colspan="1">glutamate, choline, 1,5-anhydro-D-glucitol, betaine, and methylguanidine</td><td align="left" rowspan="1" colspan="1">LC-TOFMS and GC-TOFMS</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Xie</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Metabolite</td><td align="left" rowspan="1" colspan="1">glutamate, choline, 1,5-anhydro-D-glucitol, betaine, and methylguanidine</td><td align="left" rowspan="1" colspan="1">LC-TOFMS and GC-TOFMS</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Zhang</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">Metabolite</td><td align="left" rowspan="1" colspan="1">serum unsaturated fatty acids(Panel a: C16:1 Palmitoleic acid, C18:3 linolenic acid, C18:2 linoleic acid, C20:4 arachidonic acid and C22:6 docosahexaenoic acid)</td><td align="left" rowspan="1" colspan="1">CBDInanoESI-FTICR MS</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Mayerle</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Metabolite</td><td align="left" rowspan="1" colspan="1">nine plasma metabolites(Proline, Sphingomyelin (d18:2,C17:0), Phosphatidylcholine (C18:0,C22:6), Isocitrate, Sphinganine-1-phosphate (d18:0), Histidine, Pyruvate, Ceramide (d18:1,C24:0), Sphingomyelin (d17:1,C18:0))</td><td align="left" rowspan="1" colspan="1">GC-MS, LC-MS/MS</td><td align="left" rowspan="1" colspan="1">blood</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hirata</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Metabolite</td><td align="left" rowspan="1" colspan="1">metabolites(histidine, xylitol)</td><td align="left" rowspan="1" colspan="1">GC/MS/MS</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yamada</bold>
</td><td align="left" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">anti-3&#x02019;-sialyllactose antibodies</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wang</bold>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">Macrophage inhibitory cytokine 1</td><td align="left" rowspan="1" colspan="1">RT-PCR and ELISA</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Matsunaga</bold>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">S100P in Duodenal Fluid</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">Duodenal fluid</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Zhou</bold>
</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">serum glypican&#x02010;1</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Sato</bold>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">Apolipoprotein A2 isoforms (apoA2-i)</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Mawaribuchi</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">rBC2LCN-reactive SERPINA3</td><td align="left" rowspan="1" colspan="1">Lectin-ELISA, Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nam</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">Asprosin</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Han</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">Serum dickkopf-1</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kashiro</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">apolipoprotein-A2 isoforms</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">blood</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yu</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">selected protein panels: S100A11, PPY, RET, 5&#x02019;-NT, ITGB5, ERBB3, SCAMP3 and CEACAM1</td><td align="left" rowspan="1" colspan="1">Proximity Extension Assay(PEA),ELISA, ECLIA</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Mohamed</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">MIC-1</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Radon</bold>
</td><td align="left" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">LYVE-1, REG1A, and TFF1 in Urine</td><td align="left" rowspan="1" colspan="1">GeLC/MS/MS analysis and ELISA assays</td><td align="left" rowspan="1" colspan="1">Urine</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Li</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">A panel of three TAAbs (anti-HEXB, anti-TXLNA, and anti-SLAMF6)</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lee. M</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">Complement Factor B (CFB)</td><td align="left" rowspan="1" colspan="1">ELISA, ECLIA</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Brand</bold>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">Single-chain variable fragment antibody: A1026, A1048, A1065, PC105, PC150, PC157, PC165, PC242</td><td align="left" rowspan="1" colspan="1">IMMray PanCan-d test</td><td align="left" rowspan="1" colspan="1">blood</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Aronsson</bold>
</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">IL-17E, B7-1, DR6</td><td align="left" rowspan="1" colspan="1">RayBio Human Glycosylation Antibody Array 1000, RayBiotech</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Wen</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">N-glycan biosignatures</td><td align="left" rowspan="1" colspan="1">Serum glycoprotein N-glycome profiling</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Haab</bold>
</td><td align="left" rowspan="1" colspan="1">2024</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">CA199STRA+MUC16STRA+CA19&#x02013;9</td><td align="left" rowspan="1" colspan="1">Antibody microarrays, Luminex bead-based immunoassays and sandwich ELISA assay</td><td align="left" rowspan="1" colspan="1">plasma</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kim</bold>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">ApoA1&#x03001;CA125&#x03001;CA19&#x02013;9&#x03001;CEA&#x03001;ApoA2 and TTR</td><td align="left" rowspan="1" colspan="1">immunoturbidimetric method, electrochemiluminescent detection method, ELISA</td><td align="left" rowspan="1" colspan="1">blood</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Lee. D</bold>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">LRG1, TTR, CA 19&#x02013;9</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">blood</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Firpo</bold>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">31 analytes Serum Biomarker Panel: ALCAM, ANG, AXL, BAG3, BSG, CA 19&#x02013;9, CEA, CEACAM1, COL18A1, EPCAM, HA, HP, ICAM1, IGFBP2, IGFBP4, LCN2, LRG1, MMP2, MMP7, MMP9, MSLN, PARK7, PPBP, PRG4, SPARCL1, SPP1, TGFBI, THBS1, TIMP1, TNFRSF1A, VEGFC</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">serum</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Zhang</bold>
</td><td align="left" rowspan="1" colspan="1">2013</td><td align="left" rowspan="1" colspan="1">Protein</td><td align="left" rowspan="1" colspan="1">CA19&#x02013;9, ALB, CRP and IL-8</td><td align="left" rowspan="1" colspan="1">ELISA</td><td align="left" rowspan="1" colspan="1">serum</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec013"><title>Quality assessment</title><p>Using the QUADAS-2 tool (<xref rid="pone.0322720.g002" ref-type="fig">Fig 2</xref>), we found that 20 studies had a high risk of patient selection bias due to potential case-control designs and unclear enrollment processes. Twelve studies had ambiguous descriptions in this domain. One study had a high risk of bias in the index test domain due to unclear interpretation processes. All studies had a well-defined reference standard, resulting in a low risk of bias for that domain. All studies were rated low risk in the flow and timing domain due to appropriate intervals between index tests and reference standards.</p><fig position="float" id="pone.0322720.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.g002</object-id><label>Fig 2</label><caption><title> Risk of Bias and Applicability Concerns Assessment Using QUADAS-2.</title></caption><graphic xlink:href="pone.0322720.g002" position="float"/></fig></sec><sec id="sec014"><title>Diagnostic accuracy of protein biomarkers</title><p>We included 17 studies assessing protein biomarkers for early pancreatic cancer detection (<xref rid="pone.0322720.g003" ref-type="fig">Fig 3</xref>). Using a bivariate random-effects model, the pooled sensitivity was 0.79 (95% CI, 0.70&#x02013;0.86), and the pooled specificity was 0.88 (95% CI, 0.82&#x02013;0.93). Forest plots showed substantial variability, with I&#x000b2; values of 83.61% for sensitivity and 92.79% for specificity.</p><fig position="float" id="pone.0322720.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.g003</object-id><label>Fig 3</label><caption><title>Forest Plots, SROC Curve, and Diagnostic Performance Analyses of Protein Biomarkers for Early Pancreatic Cancer Detection.</title><p>A: Forest plots showing pooled sensitivity (left) and specificity (right) estimates of included studies with 95% confidence intervals (CIs). The red dashed lines indicate the overall pooled sensitivity and specificity. B: Forest plots of positive likelihood ratios (LR+) and negative likelihood ratios (LR-) with pooled estimates. LR+ measures the likelihood of a positive test result in patients with the disease, while LR- assesses the likelihood of a negative test in patients without the disease. C: Forest plots of diagnostic score (log diagnostic odds ratio) and diagnostic odds ratio (DOR) with corresponding 95% CIs. Higher DOR values indicate stronger overall diagnostic accuracy. D: Summary Receiver Operating Characteristic (SROC) curve with prediction and confidence contours, depicting the diagnostic accuracy of biomarkers across studies. The red point represents the summary operating point, and the dotted lines indicate the confidence and prediction intervals. E: Deeks&#x02019; funnel plot asymmetry test for publication bias assessment. A non-significant p-value (p&#x02009;&#x0003e;&#x02009;0.05) suggests no evidence of significant publication bias. F: Fagan&#x02019;s nomogram demonstrating post-test probabilities based on a pretest probability of 50%. Positive tests increase post-test probability to 87%, while negative tests reduce it to 19%. G: Scatter plot of positive likelihood ratio (PLR) versus negative likelihood ratio (NLR) across studies, illustrating variability in diagnostic accuracy.</p></caption><graphic xlink:href="pone.0322720.g003" position="float"/></fig><p>The SROC curve had an AUC of 0.90 (95% CI, 0.87&#x02013;0.93), demonstrating excellent diagnostic accuracy. The pooled DOR was 27.74 (95% CI, 14.32&#x02013;53.76). Significant heterogeneity was observed, emphasizing the need to investigate variability sources.</p><p>The pooled PLR was 6.64 (95% CI, 4.19&#x02013;10.52), and the pooled NLR was 0.24 (95% CI, 0.17&#x02013;0.34). Using a pretest probability of 50%, Fagan&#x02019;s nomogram showed that a positive test increased the posttest probability to 87%, while a negative test reduced it to 19%.</p><p>Deeks&#x02019; funnel plot asymmetry test yielded a p-value of 0.29, indicating no significant publication bias.</p></sec><sec id="sec015"><title>Diagnostic performance of ctDNA biomarkers</title><p>Seven studies evaluated ctDNA biomarkers (<xref rid="pone.0322720.g004" ref-type="fig">Fig 4</xref>). The pooled sensitivity was 0.65 (95% CI, 0.48&#x02013;0.81), and the pooled specificity was 0.94 (95% CI, 0.88&#x02013;0.97). Forest plots revealed significant heterogeneity, with I&#x000b2; values of 94.33% for sensitivity and 85.08% for specificity.</p><fig position="float" id="pone.0322720.g004"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.g004</object-id><label>Fig 4</label><caption><title>Forest Plots, SROC Curve, and Diagnostic Performance Analyses of ctDNA Biomarkers for Early Pancreatic Cancer Detection.</title><p>A: Forest plots showing pooled sensitivity (left) and specificity (right) estimates of included studies with 95% confidence intervals (CIs). The red dashed lines indicate the overall pooled sensitivity and specificity. B: Forest plots of positive likelihood ratios (LR+) and negative likelihood ratios (LR-) with pooled estimates. LR+ measures the likelihood of a positive test result in patients with the disease, while LR- assesses the likelihood of a negative test in patients without the disease. C: Forest plots of diagnostic score (log diagnostic odds ratio) and diagnostic odds ratio (DOR) with corresponding 95% CIs. Higher DOR values indicate stronger overall diagnostic accuracy. D: Summary Receiver Operating Characteristic (SROC) curve with prediction and confidence contours, depicting the diagnostic accuracy of biomarkers across studies. The red point represents the summary operating point, and the dotted lines indicate the confidence and prediction intervals. E: Deeks&#x02019; funnel plot asymmetry test for publication bias assessment. A non-significant p-value (p&#x02009;&#x0003e;&#x02009;0.05) suggests no evidence of significant publication bias. F: Fagan&#x02019;s nomogram showing post-test probabilities for a pretest probability of 50%. A positive test increases the post-test probability to 91%, while a negative test decreases it to 27%. G: Scatter plot of positive likelihood ratio (PLR) versus negative likelihood ratio (NLR) across studies, illustrating variability in diagnostic accuracy.</p></caption><graphic xlink:href="pone.0322720.g004" position="float"/></fig><p>The SROC curve showed an AUC of 0.92 (95% CI, 0.89&#x02013;0.94). The pooled DOR was 27.73 (95% CI, 12.91&#x02013;59.55). The pooled PLR was 10.26 (95% CI, 5.75&#x02013;18.25), and the pooled NLR was 0.37 (95% CI, 0.22&#x02013;0.62). Fagan&#x02019;s nomogram indicated that a positive ctDNA result increased the posttest probability to 91%, while a negative result decreased it to 27%.</p><p>Deeks&#x02019; funnel plot asymmetry test showed no significant publication bias (p&#x02009;=&#x02009;0.29).</p></sec><sec id="sec016"><title>Diagnostic performance of miRNA biomarkers</title><p>Seven studies assessed miRNA biomarkers (<xref rid="pone.0322720.g005" ref-type="fig">Fig 5</xref>). The pooled sensitivity was 0.88 (95% CI, 0.79&#x02013;0.93), and the pooled specificity was 0.91 (95% CI, 0.82&#x02013;0.95). High heterogeneity was observed, with I&#x000b2; values of 77.36% for sensitivity and 91.27% for specificity.</p><fig position="float" id="pone.0322720.g005"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.g005</object-id><label>Fig 5</label><caption><title>Forest Plots, SROC Curve, and Diagnostic Performance Analyses of miRNA Biomarkers for Early Pancreatic Cancer Detection.</title><p>A: Forest plots showing pooled sensitivity (left) and specificity (right) estimates of included studies with 95% confidence intervals (CIs). The red dashed lines indicate the overall pooled sensitivity and specificity. B: Forest plots of positive likelihood ratios (LR+) and negative likelihood ratios (LR-) with pooled estimates. LR+ measures the likelihood of a positive test result in patients with the disease, while LR- assesses the likelihood of a negative test in patients without the disease. C: Forest plots of diagnostic score (log diagnostic odds ratio) and diagnostic odds ratio (DOR) with corresponding 95% CIs. Higher DOR values indicate stronger overall diagnostic accuracy. D: Summary Receiver Operating Characteristic (SROC) curve with prediction and confidence contours, depicting the diagnostic accuracy of biomarkers across studies. The red point represents the summary operating point, and the dotted lines indicate the confidence and prediction intervals. E: Deeks&#x02019; funnel plot asymmetry test for publication bias assessment. A non-significant p-value (p&#x02009;&#x0003e;&#x02009;0.05) suggests no evidence of significant publication bias. F: Fagan&#x02019;s nomogram demonstrating post-test probabilities based on a pretest probability of 50%. A positive test result increases the post-test probability to 91%, while a negative test reduces it to 12%. G: Scatter plot of positive likelihood ratio (PLR) versus negative likelihood ratio (NLR) across studies, illustrating variability in diagnostic accuracy.</p></caption><graphic xlink:href="pone.0322720.g005" position="float"/></fig><p>The SROC curve had an AUC of 0.95 (95% CI, 0.93&#x02013;0.97). The pooled DOR was 72.68 (95% CI, 26.64&#x02013;198.24). The pooled PLR was 9.57 (95% CI, 4.85&#x02013;18.88), and the pooled NLR was 0.13 (95% CI, 0.07&#x02013;0.24). Fagan&#x02019;s nomogram showed that a positive miRNA test increased the posttest probability to 91%, while a negative result reduced it to 12%.</p><p>Deeks&#x02019; funnel plot asymmetry test indicated no significant publication bias (p&#x02009;=&#x02009;0.45).</p></sec><sec id="sec017"><title>Diagnostic accuracy of metabolite biomarkers</title><p>Seven studies evaluated metabolite biomarkers (<xref rid="pone.0322720.g006" ref-type="fig">Fig 6</xref>). The pooled sensitivity was 0.84 (95% CI, 0.73&#x02013;0.92), and the pooled specificity was 0.85 (95% CI, 0.81&#x02013;0.88). Significant heterogeneity was present, with I&#x000b2; values of 81.17% for sensitivity and 98.05% for specificity.</p><fig position="float" id="pone.0322720.g006"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.g006</object-id><label>Fig 6</label><caption><title>Forest Plots, SROC Curve, and Diagnostic Performance Analyses of Metabolite Biomarkers for Early Pancreatic Cancer Detection.</title><p>A: Forest plots showing pooled sensitivity (left) and specificity (right) estimates of included studies with 95% confidence intervals (CIs). The red dashed lines indicate the overall pooled sensitivity and specificity. B: Forest plots of positive likelihood ratios (LR+) and negative likelihood ratios (LR-) with pooled estimates. LR+ measures the likelihood of a positive test result in patients with the disease, while LR- assesses the likelihood of a negative test in patients without the disease. C: Forest plots of diagnostic score (log diagnostic odds ratio) and diagnostic odds ratio (DOR) with corresponding 95% CIs. Higher DOR values indicate stronger overall diagnostic accuracy. D: Summary Receiver Operating Characteristic (SROC) curve with prediction and confidence contours, depicting the diagnostic accuracy of biomarkers across studies. The red point represents the summary operating point, and the dotted lines indicate the confidence and prediction intervals. E: Deeks&#x02019; funnel plot asymmetry test for publication bias assessment. A non-significant p-value (p&#x02009;&#x0003e;&#x02009;0.05) suggests no evidence of significant publication bias. F: Fagan&#x02019;s nomogram demonstrating post-test probabilities. Based on a pretest probability of 50%, a positive test result increases the post-test probability to 85%, while a negative test reduces it to 15%. G: Scatter plot of positive likelihood ratio (PLR) versus negative likelihood ratio (NLR) across studies, illustrating variability in diagnostic accuracy.</p></caption><graphic xlink:href="pone.0322720.g006" position="float"/></fig><p>The SROC curve showed an AUC of 0.90 (95% CI, 0.87&#x02013;0.93). The pooled DOR was 31.76 (95% CI, 12.38&#x02013;81.48). The pooled PLR was 5.80 (95% CI, 4.10&#x02013;8.20), and the pooled NLR was 0.18 (95% CI, 0.10&#x02013;0.34). Fagan&#x02019;s nomogram indicated that a positive test increased the posttest probability to 85%, while a negative result reduced it to 15%.</p><p>Deeks&#x02019; funnel plot asymmetry test suggested potential publication bias (p&#x02009;=&#x02009;0.04), so these results should be interpreted with caution.</p></sec><sec id="sec018"><title>Subgroup analysis results</title><p>We conducted subgroup analyses on proteins, ctDNA, miRNAs, and metabolites. When novel biomarkers are combined with CA19&#x02013;9, the diagnostic performance exceeds what can be achieved by using these biomarkers alone. In this study, we began by conducting a meta-analysis to determine the overall performance of novel biomarkers used in conjunction with CA19&#x02013;9. We then closely examined the definitions and calculation methods employed in the relevant articles and observed two primary strategies.</p><p>The first strategy, known as the &#x0201c;either-positive&#x0201d; approach, calculates sensitivity by classifying a patient&#x02019;s overall result as positive if either CA19&#x02013;9 or the novel biomarker is positive. Specificity, on the other hand, is determined by requiring both tests to be negative&#x02014;referred to as &#x0201c;joint negativity.&#x0201d; In other words, this approach applies an &#x0201c;OR&#x0201d; principle for positivity and an &#x0201c;AND&#x0201d; principle for negativity. By contrast, some studies utilized regression models, scoring systems, or machine learning algorithms (e.g., logistic regression or multi-marker panels) to estimate the combined sensitivity and specificity of a biomarker with CA19&#x02013;9. Under these methods, an integrated score or a predicted probability serves as a threshold: results above this threshold are classified as positive, and those below are classified as negative. Consequently, in such cases, the reported sensitivity and specificity arise from modeling or receiver operating characteristic (ROC) analysis rather than a simple binary combination. Based on these distinctions, we conducted subgroup analyses for each approach.</p><p>Fourteen studies [<xref rid="pone.0322720.ref040" ref-type="bibr">40</xref>&#x02013;<xref rid="pone.0322720.ref044" ref-type="bibr">44</xref>,<xref rid="pone.0322720.ref047" ref-type="bibr">47</xref>,<xref rid="pone.0322720.ref052" ref-type="bibr">52</xref>,<xref rid="pone.0322720.ref054" ref-type="bibr">54</xref>,<xref rid="pone.0322720.ref056" ref-type="bibr">56</xref>&#x02013;<xref rid="pone.0322720.ref061" ref-type="bibr">61</xref>] addressed the combination of protein biomarkers with CA19&#x02013;9 for early pancreatic cancer detection. The pooled analysis showed a sensitivity of 0.90 and a specificity of 0.92. After categorizing the articles by methodology, five [<xref rid="pone.0322720.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0322720.ref043" ref-type="bibr">43</xref>,<xref rid="pone.0322720.ref056" ref-type="bibr">56</xref>,<xref rid="pone.0322720.ref057" ref-type="bibr">57</xref>,<xref rid="pone.0322720.ref062" ref-type="bibr">62</xref>] studies employing the either-positive principle yielded a combined sensitivity of 0.86 and specificity of 0.88 (<xref rid="pone.0322720.s001" ref-type="supplementary-material">S1 Fig</xref>), whereas nine [<xref rid="pone.0322720.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0322720.ref041" ref-type="bibr">41</xref>,<xref rid="pone.0322720.ref044" ref-type="bibr">44</xref>,<xref rid="pone.0322720.ref047" ref-type="bibr">47</xref>,<xref rid="pone.0322720.ref054" ref-type="bibr">54</xref>,<xref rid="pone.0322720.ref058" ref-type="bibr">58</xref>&#x02013;<xref rid="pone.0322720.ref061" ref-type="bibr">61</xref>] studies using predictive models or machine learning reported a sensitivity of 0.92 and a specificity of 0.94 (<xref rid="pone.0322720.s001" ref-type="supplementary-material">S2 Fig</xref>). There was no substantial difference in I&#x000b2; between the two groups. Nevertheless, these results suggest that algorithmic approaches may modestly increase both sensitivity and specificity compared to the simpler either-positive principle.</p><p>Another five studies [<xref rid="pone.0322720.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0322720.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0322720.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0322720.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0322720.ref063" ref-type="bibr">63</xref>] investigated ctDNA in combination with CA19&#x02013;9. Of these, three employed predictive modeling or machine learning, and two adopted the either-positive approach. Because of the limited number of studies, no subgroup meta-analysis was conducted for ctDNA. The pooled results showed a sensitivity of 0.79 and a specificity of 0.95. Although this combination demonstrates relatively high specificity, there is still a need to enhance its sensitivity (<xref rid="pone.0322720.g007" ref-type="fig">Fig 7</xref>).</p><fig position="float" id="pone.0322720.g007"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.g007</object-id><label>Fig 7</label><caption><title>Combined Diagnostic Performance of CA19-9 with Protein Biomarkers and ctDNA for Early Pancreatic Cancer Detection.</title></caption><graphic xlink:href="pone.0322720.g007" position="float"/></fig><p>Studies using healthy volunteers as controls showed similar diagnostic performance to those including patients with precancerous conditions or chronic pancreatitis, indicating that these biomarkers may not have the high false-positive rates associated with CA19&#x02013;9 in certain populations (<xref rid="pone.0322720.g008" ref-type="fig">Fig 8</xref>).</p><fig position="float" id="pone.0322720.g008"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.g008</object-id><label>Fig 8</label><caption><title>Diagnostic Performance of Biomarkers in Healthy Control Populations for Early Pancreatic Cancer Detection.</title></caption><graphic xlink:href="pone.0322720.g008" position="float"/></fig><p>Additional analyses specifically examined studies employing ELISA for protein biomarkers and PCR for miRNA biomarkers. Neither the diagnostic accuracy nor the observed heterogeneity demonstrated significant changes within these subgroups (<xref rid="pone.0322720.g009" ref-type="fig">Fig 9</xref>).</p><fig position="float" id="pone.0322720.g009"><object-id pub-id-type="doi">10.1371/journal.pone.0322720.g009</object-id><label>Fig 9</label><caption><title>Diagnostic Accuracy of Protein Biomarkers and miRNAs Using Specific Detection Methods for Early Pancreatic Cancer.</title></caption><graphic xlink:href="pone.0322720.g009" position="float"/></fig></sec><sec id="sec019"><title>Sensitivity analysis</title><p>We performed sensitivity analyses by excluding studies with high risk of bias and small sample sizes (n&#x02009;&#x02264;&#x02009;50). Reanalyzing the data showed no significant changes in pooled estimates. A leave-one-out analysis indicated that no single study unduly influenced the overall results, suggesting robustness (<xref rid="pone.0322720.s001" ref-type="supplementary-material">S7 Table</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec020"><title>Discussion</title><p>This meta-analysis evaluated the diagnostic accuracy of novel biomarkers&#x02014;protein biomarkers, ctDNA, miRNAs, and metabolites&#x02014;for early pancreatic cancer detection. Our findings show that these biomarkers have good diagnostic performance, with miRNA biomarkers exhibiting the highest pooled sensitivity and specificity, followed by protein and metabolite biomarkers. Although ctDNA biomarkers had high specificity, their sensitivity was moderate; however, sensitivity improved after excluding small-sample studies. These results highlight the potential of these biomarkers in enhancing early detection, crucial for improving patient outcomes.</p><p>Our results align with studies reporting high diagnostic accuracy of miRNAs in pancreatic cancer detection [<xref rid="pone.0322720.ref064" ref-type="bibr">64</xref>&#x02013;<xref rid="pone.0322720.ref067" ref-type="bibr">67</xref>]. The high sensitivity and specificity of miRNA biomarkers may be due to their stability in bodily fluids and role in gene regulation related to carcinogenesis [<xref rid="pone.0322720.ref068" ref-type="bibr">68</xref>]. Protein biomarkers also showed strong diagnostic performance, consistent with research emphasizing their potential in cancer diagnosis [<xref rid="pone.0322720.ref069" ref-type="bibr">69</xref>,<xref rid="pone.0322720.ref070" ref-type="bibr">70</xref>]. The moderate sensitivity but high specificity of ctDNA biomarkers reflect challenges in detecting low levels of tumor-derived DNA in early-stage disease [<xref rid="pone.0322720.ref071" ref-type="bibr">71</xref>]. Metabolite biomarkers demonstrated good diagnostic accuracy, supporting findings that metabolic changes indicate tumor presence and progression [<xref rid="pone.0322720.ref072" ref-type="bibr">72</xref>].</p><p>Unlike previous analyses focusing on all pancreatic cancer patients, our study specifically analyzed stage I and II patients. These biomarkers showed stronger diagnostic performance in early-stage diagnosis compared to overall pancreatic cancer populations.</p><p>The high sensitivity and specificity of miRNA and protein biomarkers suggest they could be effective noninvasive tools for early detection. miRNAs may reflect early molecular changes in carcinogenesis, and protein biomarkers can be detected through established assays like ELISA, offering practical clinical advantages. The high specificity of ctDNA biomarkers indicates potential for confirming diagnoses, though combining them with other biomarkers or imaging may enhance effectiveness. Metabolite biomarkers provide another detection avenue but may require standardized platforms for consistency.</p><p>Incorporating these novel biomarkers into clinical practice could significantly improve early detection rates, increasing eligibility for curative surgery. Combining them with the traditional CA19&#x02013;9 assay could enhance diagnostic accuracy, as our subgroup analyses showed improved performance with combined use. This approach could mitigate individual biomarker limitations and offer a more comprehensive diagnostic tool. In addition, our study performed a regrouped subgroup analysis of the literature on combining the novel biomarkers with CA19&#x02013;9. Some studies used an &#x0201c;either-positive&#x0201d; principle&#x02014;treating a test result as positive if either CA19&#x02013;9 or the novel biomarker was positive&#x02014;an approach that tends to increase sensitivity in clinical screening, while applying a &#x0201c;joint negativity principle&#x0201d; to enhance specificity. Other studies employed regression equations, machine learning algorithms, or multi-marker predictive models to integrate multiple variables into a single composite score, using a specified threshold to determine positivity or negativity. The subgroup analysis showed that, for protein biomarkers combined with CA19&#x02013;9, the overall sensitivity and specificity under the either-positive principle (0.86 and 0.88, respectively) were slightly lower than those achieved by predictive modeling or machine learning methods 0.92 and 0.94, respectively). These findings underscore the importance of algorithmic optimization for improving diagnostic accuracy. They also point to the potential necessity and feasibility of incorporating additional biomarkers or refining detection techniques and algorithms to further enhance diagnostic performance. Our analyses also indicated that diagnostic performance was unaffected by control group composition, suggesting these biomarkers may avoid CA19&#x02013;9&#x02019;s high false-positive rates in certain populations.</p><p>A major strength of this meta-analysis is the comprehensive evaluation across numerous studies, providing a reliable assessment of diagnostic performance. We used strict inclusion criteria and quality assessments, which enhanced the robustness of our findings. The statistical approach we employed was a random-effects meta-analysis model, which accounts for between-study variability by assuming that the true effect sizes may differ across studies. This model was chosen to accommodate the heterogeneity observed in study designs, patient populations, biomarkers, and detection methods. By using this model, we were able to calculate pooled estimates of sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) with 95% confidence intervals. Additionally, we constructed summary receiver operating characteristic (SROC) curves to assess overall diagnostic accuracy.</p><p>However, significant heterogeneity existed, likely due to biomarker diversity and differences in study design, patient populations, cancer staging, control groups, and detection methods. Potential publication bias, especially in metabolite studies, suggests caution and may relate to sample size. Sensitivity analyses did not show significant heterogeneity associated with very large or small sample sizes. Despite efforts to explore heterogeneity sources, residual variability remains. Methodological quality varied among studies, which may have influenced the pooled estimates.</p><p>Future research should focus on standardizing detection and validation methods through large, multicenter prospective studies. Developing standardized protocols for sample handling is crucial for clinical translation. Although biomarkers were pooled by type to estimate the overall diagnostic accuracy of each class (miRNAs, proteins, ctDNA), we acknowledge that individual biomarkers within each category may exhibit different cut-off values, sensitivities, and specificities. This variability can limit the generalizability of the pooled estimates. Therefore, future studies should prioritize the validation of specific biomarker combinations rather than isolated markers, and standardize detection methods and cut-off values within each biomarker type to improve diagnostic accuracy and consistency. Furthermore, exploring the combined use of biomarkers and integrating them with imaging techniques could enhance diagnostic performance. Finally, investigating the cost-effectiveness and feasibility of routine screening, especially for high-risk populations, is essential for practical clinical application.</p></sec><sec sec-type="conclusions" id="sec021"><title>Conclusion</title><p>This meta-analysis highlights the promising diagnostic performance of novel biomarkers, particularly miRNA and protein biomarkers, in early pancreatic cancer detection. Despite challenges from heterogeneity and methodological differences, these biomarkers offer potential for improving early diagnosis and patient prognosis. Further investigation through well-designed prospective studies is warranted to integrate these biomarkers into clinical practice.</p></sec><sec id="sec022" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0322720.s001" position="float" content-type="local-data"><label>S1 file</label><caption><title>Supporting information.</title><p>S1 Fig. Sensitivity with CA19&#x02013;9&#x02009;+&#x02009;Protein Biomarker (Either-Positive).S2 Fig. Sensitivity with CA19&#x02013;9&#x02009;+&#x02009;Protein Biomarker (Predictive/ Machine Learning). S1 Table. Detailed search strategy for the systematic review.S2 Table. QUADAS-2 review items.S3 Table. QUADAS-2 review results.S4 Table. Characteristics and diagnostic outcomes of studies using protein or ctDNA combined with CA19&#x02013;9 biomarkers.S5 Table. Characteristics and diagnostic outcomes of studies in healthy control populations.S6 Table. Diagnostic accuracy of protein biomarkers and miRNA biomarkers using specific detection methods for early pancreatic cancer.S7 Table. Results of leave-one-out analysis.</p><p>(PDF)</p></caption><media xlink:href="pone.0322720.s001.pdf"/></supplementary-material><supplementary-material id="pone.0322720.s002" position="float" content-type="local-data"><label>S2 file</label><caption><title>Table of all studies.</title><p>(PDF)</p></caption><media xlink:href="pone.0322720.s002.pdf"/></supplementary-material><supplementary-material id="pone.0322720.s003" position="float" content-type="local-data"><label>S3 file</label><caption><title>Table of data extraction.</title><p>(PDF)</p></caption><media xlink:href="pone.0322720.s003.pdf"/></supplementary-material><supplementary-material id="pone.0322720.s004" position="float" content-type="local-data"><label>S4 file</label><caption><title>PRISMA Checklist.</title><p>(PDF)</p></caption><media xlink:href="pone.0322720.s004.pdf"/></supplementary-material></sec></body><back><ack><p>Declaration of personal and funding interests: None.</p></ack><ref-list><title>References</title><ref id="pone.0322720.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Siegel</surname><given-names>RL</given-names></name>, <name><surname>Miller</surname><given-names>KD</given-names></name>, <name><surname>Jemal</surname><given-names>A</given-names></name>. <article-title>Cancer statistics, 2020</article-title>. <source>CA Cancer J Clin</source>. <year>2020</year>;<volume>70</volume>(<issue>1</issue>):<fpage>7</fpage>&#x02013;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3322/caac.21590</pub-id>
<pub-id pub-id-type="pmid">31912902</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Rahib</surname><given-names>L</given-names></name>, <name><surname>Smith</surname><given-names>BD</given-names></name>, <name><surname>Aizenberg</surname><given-names>R</given-names></name>, <name><surname>Rosenzweig</surname><given-names>AB</given-names></name>, <name><surname>Fleshman</surname><given-names>JM</given-names></name>, <name><surname>Matrisian</surname><given-names>LM</given-names></name>, <etal>et al</etal>. <article-title>Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States</article-title>. <source>Cancer Res</source>. <year>2014</year>;<volume>74</volume>(<issue>11</issue>):<fpage>2913</fpage>&#x02013;<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0155</pub-id>
<pub-id pub-id-type="pmid">24840647</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Hidalgo</surname><given-names>M</given-names></name>. <article-title>Pancreatic cancer</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>362</volume>(<issue>17</issue>):<fpage>1605</fpage>&#x02013;<lpage>17</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMra0901557</pub-id>
<pub-id pub-id-type="pmid">20427809</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Walter</surname><given-names>FM</given-names></name>, <name><surname>Mills</surname><given-names>K</given-names></name>, <name><surname>Mendon&#x000e7;a</surname><given-names>SC</given-names></name>, <name><surname>Abel</surname><given-names>GA</given-names></name>, <name><surname>Basu</surname><given-names>B</given-names></name>, <name><surname>Carroll</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study</article-title>. <source>Lancet Gastroenterol Hepatol</source>. <year>2016</year>;<volume>1</volume>(<issue>4</issue>):<fpage>298</fpage>&#x02013;<lpage>306</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2468-1253(16)30079-6</pub-id>
<pub-id pub-id-type="pmid">28404200</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Ren</surname><given-names>S</given-names></name>, <name><surname>Qian</surname><given-names>L-C</given-names></name>, <name><surname>Cao</surname><given-names>Y-Y</given-names></name>, <name><surname>Daniels</surname><given-names>MJ</given-names></name>, <name><surname>Song</surname><given-names>L-N</given-names></name>, <name><surname>Tian</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma</article-title>. <source>World J Gastrointest Oncol</source>. <year>2024</year>;<volume>16</volume>(<issue>4</issue>):<fpage>1256</fpage>&#x02013;<lpage>67</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4251/wjgo.v16.i4.1256</pub-id>
<pub-id pub-id-type="pmid">38660647</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>W</given-names></name>, <name><surname>Chawla</surname><given-names>A</given-names></name>, <name><surname>O&#x02019;Reilly</surname><given-names>EM</given-names></name>. <article-title>Pancreatic Cancer: A Review</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>326</volume>(<issue>9</issue>):<fpage>851</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2021.13027</pub-id>
<pub-id pub-id-type="pmid">34547082</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Siegel</surname><given-names>RL</given-names></name>, <name><surname>Giaquinto</surname><given-names>AN</given-names></name>, <name><surname>Jemal</surname><given-names>A</given-names></name>. <article-title>Cancer statistics, 2024</article-title>. <source>CA Cancer J Clin</source>. <year>2024</year>;<volume>74</volume>(<issue>1</issue>):<fpage>12</fpage>&#x02013;<lpage>49</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3322/caac.21820</pub-id>
<pub-id pub-id-type="pmid">38230766</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Singhi</surname><given-names>AD</given-names></name>, <name><surname>Koay</surname><given-names>EJ</given-names></name>, <name><surname>Chari</surname><given-names>ST</given-names></name>, <name><surname>Maitra</surname><given-names>A</given-names></name>. <article-title>Early Detection of Pancreatic Cancer: Opportunities and Challenges</article-title>. <source>Gastroenterology</source>. <year>2019</year>;<volume>156</volume>(<issue>7</issue>):<fpage>2024</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1053/j.gastro.2019.01.259</pub-id>
<pub-id pub-id-type="pmid">30721664</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>B</given-names></name>, <name><surname>Zhao</surname><given-names>B</given-names></name>, <name><surname>Chen</surname><given-names>F</given-names></name>. <article-title>Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a systematic review and meta-analysis</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2022</year>;<volume>34</volume>(<issue>9</issue>):<fpage>891</fpage>&#x02013;<lpage>904</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MEG.0000000000002415</pub-id>
<pub-id pub-id-type="pmid">35913776</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Rosty</surname><given-names>C</given-names></name>, <name><surname>Goggins</surname><given-names>M</given-names></name>. <article-title>Early detection of pancreatic carcinoma</article-title>. <source>Hematol Oncol Clin North Am</source>. <year>2002</year>;<volume>16</volume>(<issue>1</issue>):<fpage>37</fpage>&#x02013;<lpage>52</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0889-8588(01)00007-7</pub-id>
<pub-id pub-id-type="pmid">12063828</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Azizian</surname><given-names>A</given-names></name>, <name><surname>R&#x000fc;hlmann</surname><given-names>F</given-names></name>, <name><surname>Krause</surname><given-names>T</given-names></name>, <name><surname>Bernhardt</surname><given-names>M</given-names></name>, <name><surname>Jo</surname><given-names>P</given-names></name>, <name><surname>K&#x000f6;nig</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>CA19-9 for detecting recurrence of pancreatic cancer</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1332</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-020-57930-x</pub-id>
<pub-id pub-id-type="pmid">31992753</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Luo</surname><given-names>G</given-names></name>, <name><surname>Fan</surname><given-names>Z</given-names></name>, <name><surname>Cheng</surname><given-names>H</given-names></name>, <name><surname>Jin</surname><given-names>K</given-names></name>, <name><surname>Guo</surname><given-names>M</given-names></name>, <name><surname>Lu</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer</article-title>. <source>Pancreatology</source>. <year>2018</year>;<volume>18</volume>(<issue>8</issue>):<fpage>971</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.pan.2018.08.003</pub-id>
<pub-id pub-id-type="pmid">30131287</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Cao</surname><given-names>Y-Y</given-names></name>, <name><surname>Guo</surname><given-names>K</given-names></name>, <name><surname>Zhao</surname><given-names>R</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Lv</surname><given-names>X-J</given-names></name>, <name><surname>Lu</surname><given-names>Z-P</given-names></name>, <etal>et al</etal>. <article-title>Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma</article-title>. <source>Digit Health</source>. <year>2023</year>;<volume>9</volume>:<fpage>20552076231179007</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/20552076231179007</pub-id>
<pub-id pub-id-type="pmid">37312938</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>R</given-names></name>, <name><surname>Ren</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Guo</surname><given-names>K</given-names></name>, <name><surname>Lu</surname><given-names>Z</given-names></name>, <name><surname>Tian</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study</article-title>. <source>Cancer Med</source>. <year>2023</year>;<volume>12</volume>(<issue>4</issue>):<fpage>5158</fpage>&#x02013;<lpage>71</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/cam4.5296</pub-id>
<pub-id pub-id-type="pmid">36161527</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Cao</surname><given-names>Y-Y</given-names></name>, <name><surname>Lv</surname><given-names>X-J</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Qian</surname><given-names>L-C</given-names></name>, <name><surname>Si</surname><given-names>H-P</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Serum High-Density Lipoprotein Cholesterol Concentrations in Pancreatic Ductal Adenocarcinoma and Its Association With Histological Grade in a Chinese Population</article-title>. <source>Cancer Control</source>. <year>2025</year>;<volume>32</volume>:<fpage>10732748251316602</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/10732748251316602</pub-id>
<pub-id pub-id-type="pmid">39927839</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Page</surname><given-names>MJ</given-names></name>, <name><surname>Moher</surname><given-names>D</given-names></name>, <name><surname>Bossuyt</surname><given-names>PM</given-names></name>, <name><surname>Boutron</surname><given-names>I</given-names></name>, <name><surname>Hoffmann</surname><given-names>TC</given-names></name>, <name><surname>Mulrow</surname><given-names>CD</given-names></name>, <etal>et al</etal>. <article-title>PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews</article-title>. <source>BMJ</source>. <year>2021</year>;<volume>372</volume>:n160. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.n160</pub-id>
<pub-id pub-id-type="pmid">33781993</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Whiting</surname><given-names>PF</given-names></name>, <name><surname>Rutjes</surname><given-names>AWS</given-names></name>, <name><surname>Westwood</surname><given-names>ME</given-names></name>, <name><surname>Mallett</surname><given-names>S</given-names></name>, <name><surname>Deeks</surname><given-names>JJ</given-names></name>, <name><surname>Reitsma</surname><given-names>JB</given-names></name>, <etal>et al</etal>. <article-title>QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies</article-title>. <source>Ann Intern Med</source>. <year>2011</year>;<volume>155</volume>(<issue>8</issue>):<fpage>529</fpage>&#x02013;<lpage>36</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7326/0003-4819-155-8-201110180-00009</pub-id>
<pub-id pub-id-type="pmid">22007046</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Thompson</surname><given-names>SG</given-names></name>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source>. <year>2002</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1539</fpage>&#x02013;<lpage>58</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/sim.1186</pub-id>
<pub-id pub-id-type="pmid">12111919</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Higgins</surname><given-names>JPT</given-names></name>, <name><surname>Thompson</surname><given-names>SG</given-names></name>, <name><surname>Deeks</surname><given-names>JJ</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source>. <year>2003</year>;<volume>327</volume>(<issue>7414</issue>):<fpage>557</fpage>&#x02013;<lpage>60</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id>
<pub-id pub-id-type="pmid">12958120</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>JD</given-names></name>, <name><surname>Javed</surname><given-names>AA</given-names></name>, <name><surname>Thoburn</surname><given-names>C</given-names></name>, <name><surname>Wong</surname><given-names>F</given-names></name>, <name><surname>Tie</surname><given-names>J</given-names></name>, <name><surname>Gibbs</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2017</year>;<volume>114</volume>(<issue>38</issue>):<fpage>10202</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1704961114</pub-id>
<pub-id pub-id-type="pmid">28874546</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Bauden</surname><given-names>M</given-names></name>, <name><surname>Pamart</surname><given-names>D</given-names></name>, <name><surname>Ansari</surname><given-names>D</given-names></name>, <name><surname>Herzog</surname><given-names>M</given-names></name>, <name><surname>Eccleston</surname><given-names>M</given-names></name>, <name><surname>Micallef</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer</article-title>. <source>Clin Epigenetics</source>. <year>2015</year>;<volume>7</volume>:<fpage>106</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13148-015-0139-4</pub-id>
<pub-id pub-id-type="pmid">26451166</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Eissa</surname><given-names>MAL</given-names></name>, <name><surname>Lerner</surname><given-names>L</given-names></name>, <name><surname>Abdelfatah</surname><given-names>E</given-names></name>, <name><surname>Shankar</surname><given-names>N</given-names></name>, <name><surname>Canner</surname><given-names>JK</given-names></name>, <name><surname>Hasan</surname><given-names>NM</given-names></name>, <etal>et al</etal>. <article-title>Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood</article-title>. <source>Clin Epigenetics</source>. <year>2019</year>;<volume>11</volume>(<issue>1</issue>):<fpage>59</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13148-019-0650-0</pub-id>
<pub-id pub-id-type="pmid">30953539</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Fujimoto</surname><given-names>Y</given-names></name>, <name><surname>Suehiro</surname><given-names>Y</given-names></name>, <name><surname>Kaino</surname><given-names>S</given-names></name>, <name><surname>Suenaga</surname><given-names>S</given-names></name>, <name><surname>Tsuyama</surname><given-names>T</given-names></name>, <name><surname>Matsui</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer</article-title>. <source>Oncology</source>. <year>2021</year>;<volume>99</volume>(<issue>4</issue>):<fpage>234</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1159/000511940</pub-id>
<pub-id pub-id-type="pmid">33440396</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Henriksen</surname><given-names>SD</given-names></name>, <name><surname>Madsen</surname><given-names>PH</given-names></name>, <name><surname>Larsen</surname><given-names>AC</given-names></name>, <name><surname>Johansen</surname><given-names>MB</given-names></name>, <name><surname>Drewes</surname><given-names>AM</given-names></name>, <name><surname>Pedersen</surname><given-names>IS</given-names></name>, <etal>et al</etal>. <article-title>Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma</article-title>. <source>Clin Epigenetics</source>. <year>2016</year>;<volume>8</volume>:<fpage>117</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13148-016-0286-2</pub-id>
<pub-id pub-id-type="pmid">27891190</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Majumder</surname><given-names>S</given-names></name>, <name><surname>Taylor</surname><given-names>WR</given-names></name>, <name><surname>Foote</surname><given-names>PH</given-names></name>, <name><surname>Berger</surname><given-names>CK</given-names></name>, <name><surname>Wu</surname><given-names>CW</given-names></name>, <name><surname>Mahoney</surname><given-names>DW</given-names></name>, <etal>et al</etal>. <article-title>High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9</article-title>. <source>Clin Cancer Res</source>. <year>2021</year>;<volume>27</volume>(<issue>9</issue>):<fpage>2523</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-0235</pub-id>
<pub-id pub-id-type="pmid">33593879</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>H</given-names></name>, <name><surname>Guo</surname><given-names>S</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Su</surname><given-names>Z</given-names></name>, <name><surname>He</surname><given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA</article-title>. <source>BMC Med</source>. <year>2022</year>;<volume>20</volume>(<issue>1</issue>):<fpage>458</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12916-022-02647-z</pub-id>
<pub-id pub-id-type="pmid">36434648</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Debernardi</surname><given-names>S</given-names></name>, <name><surname>Massat</surname><given-names>NJ</given-names></name>, <name><surname>Radon</surname><given-names>TP</given-names></name>, <name><surname>Sangaralingam</surname><given-names>A</given-names></name>, <name><surname>Banissi</surname><given-names>A</given-names></name>, <name><surname>Ennis</surname><given-names>DP</given-names></name>, <etal>et al</etal>. <article-title>Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma</article-title>. <source>Am J Cancer Res</source>. <year>2015</year>;<volume>5</volume>(<issue>11</issue>):<fpage>3455</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="pmid">26807325</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Masterson</surname><given-names>AN</given-names></name>, <name><surname>Chowdhury</surname><given-names>NN</given-names></name>, <name><surname>Fang</surname><given-names>Y</given-names></name>, <name><surname>Yip-Schneider</surname><given-names>MT</given-names></name>, <name><surname>Hati</surname><given-names>S</given-names></name>, <name><surname>Gupta</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Amplification-Free, High-Throughput Nanoplasmonic Quantification of Circulating MicroRNAs in Unprocessed Plasma Microsamples for Earlier Pancreatic Cancer Detection</article-title>. <source>ACS Sens</source>. <year>2023</year>;<volume>8</volume>(<issue>3</issue>):<fpage>1085</fpage>&#x02013;<lpage>100</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acssensors.2c02105</pub-id>
<pub-id pub-id-type="pmid">36853001</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>Y</given-names></name>, <name><surname>Tong</surname><given-names>Y</given-names></name>, <name><surname>Zhong</surname><given-names>A</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Lu</surname><given-names>R</given-names></name>, <name><surname>Guo</surname><given-names>L</given-names></name>. <article-title>Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer</article-title>. <source>Medicine (Baltimore)</source>. <year>2020</year>;<volume>99</volume>(<issue>52</issue>):e23863. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MD.0000000000023863</pub-id>
<pub-id pub-id-type="pmid">33350781</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Nakamura</surname><given-names>K</given-names></name>, <name><surname>Zhu</surname><given-names>Z</given-names></name>, <name><surname>Roy</surname><given-names>S</given-names></name>, <name><surname>Jun</surname><given-names>E</given-names></name>, <name><surname>Han</surname><given-names>H</given-names></name>, <name><surname>Munoz</surname><given-names>RM</given-names></name>, <etal>et al</etal>. <article-title>An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study</article-title>. <source>Gastroenterology</source>. <year>2022</year>;<volume>163</volume>(<issue>5</issue>):1252-1266.e2. <comment>doi: </comment><pub-id pub-id-type="doi">10.1053/j.gastro.2022.06.090</pub-id>
<pub-id pub-id-type="pmid">35850192</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>J</given-names></name>, <name><surname>Gao</surname><given-names>G</given-names></name>, <name><surname>Ge</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Cui</surname><given-names>H</given-names></name>, <name><surname>Zheng</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer: A Multicenter Cohort Study</article-title>. <source>Dig Dis Sci</source>. <year>2024</year>;<volume>69</volume>(<issue>4</issue>):<fpage>1263</fpage>&#x02013;<lpage>73</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10620-024-08338-4</pub-id>
<pub-id pub-id-type="pmid">38451429</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Schultz</surname><given-names>NA</given-names></name>, <name><surname>Dehlendorff</surname><given-names>C</given-names></name>, <name><surname>Jensen</surname><given-names>BV</given-names></name>, <name><surname>Bjerregaard</surname><given-names>JK</given-names></name>, <name><surname>Nielsen</surname><given-names>KR</given-names></name>, <name><surname>Bojesen</surname><given-names>SE</given-names></name>, <etal>et al</etal>. <article-title>MicroRNA biomarkers in whole blood for detection of pancreatic cancer</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>311</volume>(<issue>4</issue>):<fpage>392</fpage>&#x02013;<lpage>404</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2013.284664</pub-id>
<pub-id pub-id-type="pmid">24449318</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref033"><label>33</label><mixed-citation publication-type="journal">PubMed . <name><surname>Ganepola</surname><given-names>GA</given-names></name>, <name><surname>Rutledge</surname><given-names>JR</given-names></name>, <name><surname>Suman</surname><given-names>P</given-names></name>, <name><surname>Yiengpruksawan</surname><given-names>A</given-names></name>, <name><surname>Chang</surname><given-names>DH</given-names></name>. <article-title>Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer</article-title>. <source>World J Gastrointest Oncol</source>. <year>2014</year>;<volume>6</volume>(<issue>1</issue>):<fpage>22</fpage>&#x02013;<lpage>33</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4251/wjgo.v6.i1.22</pub-id>
<pub-id pub-id-type="pmid">24578785</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Wolrab</surname><given-names>D</given-names></name>, <name><surname>Jir&#x000e1;sko</surname><given-names>R</given-names></name>, <name><surname>C&#x000ed;fkov&#x000e1;</surname><given-names>E</given-names></name>, <name><surname>H&#x000f6;ring</surname><given-names>M</given-names></name>, <name><surname>Mei</surname><given-names>D</given-names></name>, <name><surname>Chocholou&#x00161;kov&#x000e1;</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Lipidomic profiling of human serum enables detection of pancreatic cancer</article-title>. <source>Nat Commun</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>124</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-27765-9</pub-id>
<pub-id pub-id-type="pmid">35013261</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Fukutake</surname><given-names>N</given-names></name>, <name><surname>Ueno</surname><given-names>M</given-names></name>, <name><surname>Hiraoka</surname><given-names>N</given-names></name>, <name><surname>Shimada</surname><given-names>K</given-names></name>, <name><surname>Shiraishi</surname><given-names>K</given-names></name>, <name><surname>Saruki</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>A Novel Multivariate Index for Pancreatic Cancer Detection Based On the Plasma Free Amino Acid Profile</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>7</issue>):e0132223. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0132223</pub-id>
<pub-id pub-id-type="pmid">26133769</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>G</given-names></name>, <name><surname>Lu</surname><given-names>L</given-names></name>, <name><surname>Qiu</surname><given-names>Y</given-names></name>, <name><surname>Ni</surname><given-names>Q</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Gao</surname><given-names>Y-T</given-names></name>, <etal>et al</etal>. <article-title>Plasma metabolite biomarkers for the detection of pancreatic cancer</article-title>. <source>J Proteome Res</source>. <year>2015</year>;<volume>14</volume>(<issue>2</issue>):<fpage>1195</fpage>&#x02013;<lpage>202</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/pr501135f</pub-id>
<pub-id pub-id-type="pmid">25429707</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Qiu</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Qin</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>. <article-title>High-throughput and high-sensitivity quantitative analysis of serum unsaturated fatty acids by chip-based nanoelectrospray ionization-Fourier transform ion cyclotron resonance mass spectrometry: early stage diagnostic biomarkers of pancreatic cancer</article-title>. <source>Analyst</source>. <year>2014</year>;<volume>139</volume>(<issue>7</issue>):<fpage>1697</fpage>&#x02013;<lpage>706</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1039/c3an02130k</pub-id>
<pub-id pub-id-type="pmid">24551873</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Mayerle</surname><given-names>J</given-names></name>, <name><surname>Kalthoff</surname><given-names>H</given-names></name>, <name><surname>Reszka</surname><given-names>R</given-names></name>, <name><surname>Kamlage</surname><given-names>B</given-names></name>, <name><surname>Peter</surname><given-names>E</given-names></name>, <name><surname>Schniewind</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis</article-title>. <source>Gut</source>. <year>2018</year>;<volume>67</volume>(<issue>1</issue>):<fpage>128</fpage>&#x02013;<lpage>37</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/gutjnl-2016-312432</pub-id>
<pub-id pub-id-type="pmid">28108468</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Hirata</surname><given-names>Y</given-names></name>, <name><surname>Kobayashi</surname><given-names>T</given-names></name>, <name><surname>Nishiumi</surname><given-names>S</given-names></name>, <name><surname>Yamanaka</surname><given-names>K</given-names></name>, <name><surname>Nakagawa</surname><given-names>T</given-names></name>, <name><surname>Fujigaki</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics</article-title>. <source>Clin Chim Acta</source>. <year>2017</year>;<volume>468</volume>:<fpage>98</fpage>&#x02013;<lpage>104</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cca.2017.02.011</pub-id>
<pub-id pub-id-type="pmid">28215548</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Aronsson</surname><given-names>L</given-names></name>, <name><surname>Andersson</surname><given-names>R</given-names></name>, <name><surname>Bauden</surname><given-names>M</given-names></name>, <name><surname>Andersson</surname><given-names>B</given-names></name>, <name><surname>Bygott</surname><given-names>T</given-names></name>, <name><surname>Ansari</surname><given-names>D</given-names></name>. <article-title>High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm</article-title>. <source>Scand J Gastroenterol</source>. <year>2018</year>;<volume>53</volume>(<issue>12</issue>):<fpage>1597</fpage>&#x02013;<lpage>603</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/00365521.2018.1532020</pub-id>
<pub-id pub-id-type="pmid">30509115</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Brand</surname><given-names>RE</given-names></name>, <name><surname>Persson</surname><given-names>J</given-names></name>, <name><surname>Bratlie</surname><given-names>SO</given-names></name>, <name><surname>Chung</surname><given-names>DC</given-names></name>, <name><surname>Katona</surname><given-names>BW</given-names></name>, <name><surname>Carrato</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study</article-title>. <source>Clin Transl Gastroenterol</source>. <year>2022</year>;<volume>13</volume>(<issue>3</issue>):e00468. <comment>doi: </comment><pub-id pub-id-type="doi">10.14309/ctg.0000000000000468</pub-id>
<pub-id pub-id-type="pmid">35166713</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>S</given-names></name>, <name><surname>Zhou</surname><given-names>X</given-names></name>, <name><surname>Sui</surname><given-names>X</given-names></name>, <name><surname>He</surname><given-names>C</given-names></name>, <name><surname>Cai</surname><given-names>M</given-names></name>, <name><surname>Ma</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer</article-title>. <source>Oncotarget</source>. <year>2015</year>;<volume>6</volume>(<issue>23</issue>):<fpage>19907</fpage>&#x02013;<lpage>17</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18632/oncotarget.4529</pub-id>
<pub-id pub-id-type="pmid">26101916</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Kashiro</surname><given-names>A</given-names></name>, <name><surname>Kobayashi</surname><given-names>M</given-names></name>, <name><surname>Oh</surname><given-names>T</given-names></name>, <name><surname>Miyamoto</surname><given-names>M</given-names></name>, <name><surname>Atsumi</surname><given-names>J</given-names></name>, <name><surname>Nagashima</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer</article-title>. <source>J Gastroenterol</source>. <year>2024</year>;<volume>59</volume>(<issue>3</issue>):<fpage>263</fpage>&#x02013;<lpage>78</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00535-023-02072-w</pub-id>
<pub-id pub-id-type="pmid">38261000</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>MJ</given-names></name>, <name><surname>Na</surname><given-names>K</given-names></name>, <name><surname>Shin</surname><given-names>H</given-names></name>, <name><surname>Kim</surname><given-names>C-Y</given-names></name>, <name><surname>Cho</surname><given-names>J-Y</given-names></name>, <name><surname>Kang</surname><given-names>CM</given-names></name>, <etal>et al</etal>. <article-title>Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role</article-title>. <source>J Proteome Res</source>. <year>2021</year>;<volume>20</volume>(<issue>12</issue>):<fpage>5315</fpage>&#x02013;<lpage>28</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acs.jproteome.1c00805</pub-id>
<pub-id pub-id-type="pmid">34766501</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>T</given-names></name>, <name><surname>Xia</surname><given-names>J</given-names></name>, <name><surname>Yun</surname><given-names>H</given-names></name>, <name><surname>Sun</surname><given-names>G</given-names></name>, <name><surname>Shen</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma</article-title>. <source>Cancer Cell Int</source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>273</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12935-023-03107-1</pub-id>
<pub-id pub-id-type="pmid">37974212</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Matsunaga</surname><given-names>T</given-names></name>, <name><surname>Ohtsuka</surname><given-names>T</given-names></name>, <name><surname>Asano</surname><given-names>K</given-names></name>, <name><surname>Kimura</surname><given-names>H</given-names></name>, <name><surname>Ohuchida</surname><given-names>K</given-names></name>, <name><surname>Kitada</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma</article-title>. <source>Pancreas</source>. <year>2017</year>;<volume>46</volume>(<issue>10</issue>):<fpage>1288</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MPA.0000000000000940</pub-id>
<pub-id pub-id-type="pmid">28984789</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Mawaribuchi</surname><given-names>S</given-names></name>, <name><surname>Shimomura</surname><given-names>O</given-names></name>, <name><surname>Oda</surname><given-names>T</given-names></name>, <name><surname>Hiemori</surname><given-names>K</given-names></name>, <name><surname>Shimizu</surname><given-names>K</given-names></name>, <name><surname>Yamase</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>rBC2LCN-reactive SERPINA3 is a glycobiomarker candidate for pancreatic ductal adenocarcinoma</article-title>. <source>Glycobiology</source>. <year>2023</year>;<volume>33</volume>(<issue>4</issue>):<fpage>342</fpage>&#x02013;<lpage>52</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/glycob/cwad009</pub-id>
<pub-id pub-id-type="pmid">36728830</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Mohamed</surname><given-names>AA</given-names></name>, <name><surname>Soliman</surname><given-names>H</given-names></name>, <name><surname>Ismail</surname><given-names>M</given-names></name>, <name><surname>Ziada</surname><given-names>D</given-names></name>, <name><surname>Farid</surname><given-names>TM</given-names></name>, <name><surname>Aref</surname><given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer</article-title>. <source>Pancreatology</source>. <year>2015</year>;<volume>15</volume>(<issue>1</issue>):<fpage>34</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.pan.2014.10.008</pub-id>
<pub-id pub-id-type="pmid">25464937</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Nam</surname><given-names>H</given-names></name>, <name><surname>Hong</surname><given-names>S-S</given-names></name>, <name><surname>Jung</surname><given-names>KH</given-names></name>, <name><surname>Kang</surname><given-names>S</given-names></name>, <name><surname>Park</surname><given-names>MS</given-names></name>, <name><surname>Kang</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes</article-title>. <source>J Natl Cancer Inst</source>. <year>2022</year>;<volume>114</volume>(<issue>2</issue>):<fpage>228</fpage>&#x02013;<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/jnci/djab191</pub-id>
<pub-id pub-id-type="pmid">34613397</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Radon</surname><given-names>TP</given-names></name>, <name><surname>Massat</surname><given-names>NJ</given-names></name>, <name><surname>Jones</surname><given-names>R</given-names></name>, <name><surname>Alrawashdeh</surname><given-names>W</given-names></name>, <name><surname>Dumartin</surname><given-names>L</given-names></name>, <name><surname>Ennis</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma</article-title>. <source>Clin Cancer Res</source>. <year>2015</year>;<volume>21</volume>(<issue>15</issue>):<fpage>3512</fpage>&#x02013;<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2467</pub-id>
<pub-id pub-id-type="pmid">26240291</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Sato</surname><given-names>Y</given-names></name>, <name><surname>Kobayashi</surname><given-names>T</given-names></name>, <name><surname>Nishiumi</surname><given-names>S</given-names></name>, <name><surname>Okada</surname><given-names>A</given-names></name>, <name><surname>Fujita</surname><given-names>T</given-names></name>, <name><surname>Sanuki</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer</article-title>. <source>Cancers (Basel)</source>. <year>2020</year>;<volume>12</volume>(<issue>9</issue>):<fpage>2625</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cancers12092625</pub-id>
<pub-id pub-id-type="pmid">32937962</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Tian</surname><given-names>H</given-names></name>, <name><surname>Qi</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Fu</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma</article-title>. <source>BMC Cancer</source>. <year>2014</year>;<volume>14</volume>:<fpage>578</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1471-2407-14-578</pub-id>
<pub-id pub-id-type="pmid">25106741</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Wen</surname><given-names>Y-R</given-names></name>, <name><surname>Lin</surname><given-names>X-W</given-names></name>, <name><surname>Zhou</surname><given-names>Y-W</given-names></name>, <name><surname>Xu</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>J-L</given-names></name>, <name><surname>Chen</surname><given-names>C-Y</given-names></name>, <etal>et al</etal>. <article-title>N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer</article-title>. <source>World J Gastrointest Oncol</source>. <year>2024</year>;<volume>16</volume>(<issue>3</issue>):<fpage>659</fpage>&#x02013;<lpage>69</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4251/wjgo.v16.i3.659</pub-id>
<pub-id pub-id-type="pmid">38577461</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Yamada</surname><given-names>K</given-names></name>, <name><surname>Higashi</surname><given-names>K</given-names></name>, <name><surname>Nagahori</surname><given-names>H</given-names></name>, <name><surname>Saito</surname><given-names>K</given-names></name>. <article-title>Circulating natural antibodies against 3&#x02019;-sialyllactose complement the diagnostic performance of CA19-9 for the early detection of pancreatic ductal adenocarcinoma</article-title>. <source>Cancer Biomark</source>. <year>2020</year>;<volume>27</volume>(<issue>1</issue>):<fpage>121</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3233/CBM-190158</pub-id>
<pub-id pub-id-type="pmid">31771041</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>J</given-names></name>, <name><surname>Ploner</surname><given-names>A</given-names></name>, <name><surname>Kordes</surname><given-names>M</given-names></name>, <name><surname>L&#x000f6;hr</surname><given-names>M</given-names></name>, <name><surname>Nilsson</surname><given-names>M</given-names></name>, <name><surname>de Maturana</surname><given-names>MEL</given-names></name>, <etal>et al</etal>. <article-title>Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma</article-title>. <source>Int J Cancer</source>. <year>2021</year>;<volume>148</volume>(<issue>8</issue>):<fpage>2048</fpage>&#x02013;<lpage>58</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ijc.33464</pub-id>
<pub-id pub-id-type="pmid">33411965</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>C-Y</given-names></name>, <name><surname>Dong</surname><given-names>Y-P</given-names></name>, <name><surname>Sun</surname><given-names>X</given-names></name>, <name><surname>Sui</surname><given-names>X</given-names></name>, <name><surname>Zhu</surname><given-names>H</given-names></name>, <name><surname>Zhao</surname><given-names>Y-Q</given-names></name>, <etal>et al</etal>. <article-title>High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma</article-title>. <source>Cancer Med</source>. <year>2018</year>;<volume>7</volume>(<issue>11</issue>):<fpage>5525</fpage>&#x02013;<lpage>33</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/cam4.1833</pub-id>
<pub-id pub-id-type="pmid">30358133</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Haab</surname><given-names>B</given-names></name>, <name><surname>Qian</surname><given-names>L</given-names></name>, <name><surname>Staal</surname><given-names>B</given-names></name>, <name><surname>Jain</surname><given-names>M</given-names></name>, <name><surname>Fahrmann</surname><given-names>J</given-names></name>, <name><surname>Worthington</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Abstract A014: Combinations of previously reported biomarkers achieve improved sensitivity and specificity of detection of early stage pancreatic ductal adenocarcinoma</article-title>. <source>Cancer Research</source>. <year>2024</year>;<volume>84</volume>(2_Supplement):A014&#x02013;<lpage>A014</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1158/1538-7445.panca2023-a014</pub-id></mixed-citation></ref><ref id="pone.0322720.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>H</given-names></name>, <name><surname>Kang</surname><given-names>KN</given-names></name>, <name><surname>Shin</surname><given-names>YS</given-names></name>, <name><surname>Byun</surname><given-names>Y</given-names></name>, <name><surname>Han</surname><given-names>Y</given-names></name>, <name><surname>Kwon</surname><given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma</article-title>. <source>Cancers (Basel)</source>. <year>2020</year>;<volume>12</volume>(<issue>6</issue>):<fpage>1443</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cancers12061443</pub-id>
<pub-id pub-id-type="pmid">32492943</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Firpo</surname><given-names>MA</given-names></name>, <name><surname>Boucher</surname><given-names>KM</given-names></name>, <name><surname>Bleicher</surname><given-names>J</given-names></name>, <name><surname>Khanderao</surname><given-names>GD</given-names></name>, <name><surname>Rosati</surname><given-names>A</given-names></name>, <name><surname>Poruk</surname><given-names>KE</given-names></name>, <etal>et al</etal>. <article-title>Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma</article-title>. <source>JCO Clin Cancer Inform</source>. <year>2023</year>;<volume>7</volume>:e2200160. <comment>doi: </comment><pub-id pub-id-type="doi">10.1200/CCI.22.00160</pub-id>
<pub-id pub-id-type="pmid">36913644</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>DH</given-names></name>, <name><surname>Yoon</surname><given-names>W</given-names></name>, <name><surname>Lee</surname><given-names>A</given-names></name>, <name><surname>Han</surname><given-names>Y</given-names></name>, <name><surname>Byun</surname><given-names>Y</given-names></name>, <name><surname>Kang</surname><given-names>JS</given-names></name>, <etal>et al</etal>. <article-title>Multi-biomarker panel prediction model for diagnosis of pancreatic cancer</article-title>. <source>J Hepato-Biliary-Pancreatic Sci</source>. <year>2023</year>;<volume>30</volume>(<issue>1</issue>):<fpage>122</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jhbp.986</pub-id> PubMed .</mixed-citation></ref><ref id="pone.0322720.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>P</given-names></name>, <name><surname>Zou</surname><given-names>M</given-names></name>, <name><surname>Wen</surname><given-names>X</given-names></name>, <name><surname>Gu</surname><given-names>F</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Development of serum parameters panels for the early detection of pancreatic cancer</article-title>. <source>Int J Cancer</source>. <year>2014</year>;<volume>134</volume>(<issue>11</issue>):<fpage>2646</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ijc.28584</pub-id>
<pub-id pub-id-type="pmid">24615168</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Raimondo</surname><given-names>M</given-names></name>, <name><surname>Guha</surname><given-names>S</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Diao</surname><given-names>L</given-names></name>, <name><surname>Dong</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer</article-title>. <source>J Cancer</source>. <year>2014</year>;<volume>5</volume>(<issue>8</issue>):<fpage>696</fpage>&#x02013;<lpage>705</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7150/jca.10094</pub-id>
<pub-id pub-id-type="pmid">25258651</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Majumder</surname><given-names>S</given-names></name>, <name><surname>Chatterjee</surname><given-names>A</given-names></name>, <name><surname>Taylor</surname><given-names>WR</given-names></name>, <name><surname>Foote</surname><given-names>PH</given-names></name>, <name><surname>Mohiuddin</surname><given-names>SAA</given-names></name>, <name><surname>Berger</surname><given-names>CK</given-names></name>, <etal>et al</etal>. <article-title>Sa301 Feasibility of detecting cancer in intraductal papillary mucinous neoplasms using plasma methylated dna markers</article-title>. <source>Gastroenterology</source>. <year>2021</year>;<volume>160</volume>(<issue>6</issue>):S-476. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0016-5085(21)01844-8</pub-id></mixed-citation></ref><ref id="pone.0322720.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Gao</surname><given-names>P</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>. <article-title>Blood-Derived microRNAs for Pancreatic Cancer Diagnosis: A Narrative Review and Meta-Analysis</article-title>. <source>Front Physiol</source>. <year>2018</year>;<volume>9</volume>:<fpage>685</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fphys.2018.00685</pub-id>
<pub-id pub-id-type="pmid">29922178</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Z-Z</given-names></name>, <name><surname>Shen</surname><given-names>L-F</given-names></name>, <name><surname>Li</surname><given-names>Y-Y</given-names></name>, <name><surname>Chen</surname><given-names>P</given-names></name>, <name><surname>Chen</surname><given-names>L-Z</given-names></name>. <article-title>Clinical utility of microRNA-378 as early diagnostic biomarker of human cancers: a meta-analysis of diagnostic test</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>(<issue>36</issue>):<fpage>58569</fpage>&#x02013;<lpage>78</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18632/oncotarget.10707</pub-id>
<pub-id pub-id-type="pmid">27448977</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>X</given-names></name>, <name><surname>Zhou</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Zhu</surname><given-names>X</given-names></name>, <name><surname>Liu</surname><given-names>H</given-names></name>. <article-title>Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer</article-title>. <source>Dis Markers</source>. <year>2018</year>;2018:<fpage>6292396</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2018/6292396</pub-id>
<pub-id pub-id-type="pmid">29887920</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Wei</surname><given-names>L</given-names></name>, <name><surname>Yao</surname><given-names>K</given-names></name>, <name><surname>Gan</surname><given-names>S</given-names></name>, <name><surname>Suo</surname><given-names>Z</given-names></name>. <article-title>Clinical utilization of serum- or plasma-based miRNAs as early detection biomarkers for pancreatic cancer: A meta-analysis up to now</article-title>. <source>Medicine (Baltimore)</source>. <year>2018</year>;<volume>97</volume>(<issue>35</issue>):e12132. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MD.0000000000012132</pub-id>
<pub-id pub-id-type="pmid">30170450</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Kathuria-Prakash</surname><given-names>N</given-names></name>, <name><surname>Dave</surname><given-names>P</given-names></name>, <name><surname>Garcia</surname><given-names>L</given-names></name>, <name><surname>Brown</surname><given-names>P</given-names></name>, <name><surname>Drakaki</surname><given-names>A</given-names></name>. <article-title>MicroRNAs in Genitourinary Malignancies: An Exciting Frontier of Cancer Diagnostics and Therapeutics</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>17</issue>):<fpage>9499</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms25179499</pub-id>
<pub-id pub-id-type="pmid">39273446</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>Y-Z</given-names></name>, <name><surname>Liu</surname><given-names>D</given-names></name>, <name><surname>Zhao</surname><given-names>Y-X</given-names></name>, <name><surname>Wang</surname><given-names>H-T</given-names></name>, <name><surname>Gao</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>. <article-title>Diagnostic performance of serum macrophage inhibitory cytokine-1 in pancreatic cancer: a meta-analysis and meta-regression analysis</article-title>. <source>DNA Cell Biol</source>. <year>2014</year>;<volume>33</volume>(<issue>6</issue>):<fpage>370</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1089/dna.2013.2237</pub-id>
<pub-id pub-id-type="pmid">24592997</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Huang</surname><given-names>C</given-names></name>, <name><surname>Shen</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Shi</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Diagnostic value of S100P for pancreatic cancer: a meta-analysis</article-title>. <source>Tumour Biol</source>. <year>2014</year>;<volume>35</volume>(<issue>10</issue>):<fpage>9479</fpage>&#x02013;<lpage>85</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s13277-014-2461-4</pub-id>
<pub-id pub-id-type="pmid">25123266</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Vlataki</surname><given-names>K</given-names></name>, <name><surname>Antonouli</surname><given-names>S</given-names></name>, <name><surname>Kalyvioti</surname><given-names>C</given-names></name>, <name><surname>Lampri</surname><given-names>E</given-names></name>, <name><surname>Kamina</surname><given-names>S</given-names></name>, <name><surname>Mauri</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Circulating Tumor DNA in the Management of Early-Stage Breast Cancer</article-title>. <source>Cells</source>. <year>2023</year>;<volume>12</volume>(<issue>12</issue>):<fpage>1573</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cells12121573</pub-id>
<pub-id pub-id-type="pmid">37371043</pub-id>
</mixed-citation></ref><ref id="pone.0322720.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Hanahan</surname><given-names>D</given-names></name>, <name><surname>Weinberg</surname><given-names>RA</given-names></name>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>. <year>2011</year>;<volume>144</volume>(<issue>5</issue>):<fpage>646</fpage>&#x02013;<lpage>74</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>
<pub-id pub-id-type="pmid">21376230</pub-id>
</mixed-citation></ref></ref-list></back><sub-article article-type="author-comment" id="pone.0322720.r001" specific-use="rebutted-decision-letter-unavailable"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322720.r001</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">23 Jan 2025</named-content>
</p></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0322720.r002" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322720.r002</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Shuai</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Shuai Ren</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Shuai Ren</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322720" id="rel-obj002" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">11 Mar 2025</named-content>
</p><p>PONE-D-25-03633The Role of Novel Biomarkers in the Early Diagnosis of Pancreatic Cancer: A Systematic Review and Meta-AnalysisPLOS ONE</p><p>Dear Dr. Song,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please submit your revised manuscript by Apr 25 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#x000a0;<email>plosone@plos.org</email> . When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link> . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link> .</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Shuai Ren</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>1. When submitting your revision, we need you to address these additional requirements.</p><p>Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p><p><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p><p>
<ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
</p><p>2. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]</p><p>Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the &#x0201c;minimal data set&#x0201d; for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (<ext-link xlink:href="https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition)." ext-link-type="uri">https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition</ext-link>).</p><p>For example, authors should submit the following data:</p><p>- The values behind the means, standard deviations and other measures reported;</p><p>- The values used to build graphs;</p><p>- The points extracted from images for analysis.</p><p>Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.</p><p>If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see <ext-link xlink:href="https://journals.plos.org/plosone/s/recommended-repositories." ext-link-type="uri">https://journals.plos.org/plosone/s/recommended-repositories</ext-link>.</p><p>If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.</p><p>3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to &#x02018;Update my Information&#x02019; (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.</p><p>4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <ext-link xlink:href="http://journals.plos.org/plosone/s/supporting-information" ext-link-type="uri">http://journals.plos.org/plosone/s/supporting-information</ext-link> .</p><p>5. As required by our policy on Data Availability, please ensure your manuscript or supplementary information includes the following:</p><p>A numbered table of all studies identified in the literature search, including those that were excluded from the analyses.&#x000a0;</p><p>For every excluded study, the table should list the reason(s) for exclusion.&#x000a0;</p><p>If any of the included studies are unpublished, include a link (URL) to the primary source or detailed information about how the content can be accessed.</p><p>A table of all data extracted from the primary research sources for the systematic review and/or meta-analysis. The table must include the following information for each study:</p><p>Name of data extractors and date of data extraction</p><p>Confirmation that the study was eligible to be included in the review.&#x000a0;</p><p>All data extracted from each study for the reported systematic review and/or meta-analysis that would be needed to replicate your analyses.</p><p>If data or supporting information were obtained from another source (e.g. correspondence with the author of the original research article), please provide the source of data and dates on which the data/information were obtained by your research group.</p><p>If applicable for your analysis, a table showing the completed risk of bias and quality/certainty assessments for each study or outcome.&#x000a0; Please ensure this is provided for each domain or parameter assessed. For example, if you used the Cochrane risk-of-bias tool for randomized trials, provide answers to each of the signalling questions for each study. If you used GRADE to assess certainty of evidence, provide judgements about each of the quality of evidence factor. This should be provided for each outcome.&#x000a0;</p><p>An explanation of how missing data were handled.</p><p>This information can be included in the main text, supplementary information, or relevant data repository. Please note that providing these underlying data is a requirement for publication in this journal, and if these data are not provided your manuscript might be rejected.</p><p>Additional Editor Comments:</p><p>In the introduction part, the authors should emphasize the dire need of diagnosis pancreatic cancer at an early stage and following references could be added: doi: 10.4251/wjgo.v16.i4.1256; doi: 10.1177/20552076231179007.</p><p>There are many other biomarkers useful for diagnosis of early-stage pancreatic cancer, following references could be added such as: doi:10.1002/cam4.5296; doi:10.1177/10732748251316602.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<bold>Comments to the Author</bold>
</p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;No</p><p>**********</p><p>2. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.</p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;No</p><p>**********</p><p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p>5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1:&#x000a0;There are several inconsistencies in the font size and type in the manuscript. Check and fix them.</p><p>When you reference a figure or table in-text, do not include the description of that figure or table)</p><p>Line 96-113 : I think you could make a table for this or list the points in bullets to make it easier to read through.</p><p>Line 104: State the full form of QUADAS-2</p><p>Study selection: How did you access interrater reliability?</p><p>Line 147-149: What guided setting a benchmark score of 3 for inclusion?</p><p>Line 176: &#x0201c;Insufficient sample size&#x0201d; could be regarded as vague. What sample size was considered insufficient and why?</p><p>Line 181: &#x0201c;Tables 1 and Table2&#x0201d; fix the typo.</p><p>Line 183-186: These sentences are confusing.</p><p>Line 211: Kindly list the major proteins identified in these studies.</p><p>Line 307: You can include the funnel plot for this finding.</p><p>Line 296: Kindly list the major metabolites identified in these studies.</p><p>Reviewer #2:&#x000a0;Manuscript ID: PONE-D-25-03633</p><p>Thank you for the opportunity to review this manuscript. The manuscript provides a comprehensive overview of biomarkers for the early diagnosis of pancreatic cancer. However, several aspects of the methodology require further elaboration.</p><p>1. The authors pooled data by biomarker type. However, even within each type, there is variability in the specific biomarkers and their cut-off values. I am not a subject expert, but I wonder how meaningful it is to combine such different biomarkers.</p><p>2. The authors state that studies with a QUADAS-2 score of 3 or higher were included. QUADAS-2 has four domains for bias and three for applicability. Could you clarify how the scoring was performed? Does a total score of 7 indicate inclusion, or was the focus only on bias? Since bias and applicability have different implications, combining them does not seem appropriate.</p><p>3. Please provide the QUADAS-2 assessment results for each study.</p><p>4. Please specify the search dates.</p><p>5. The authors report the combination of CA-19 and other biomarkers. Could you elaborate on how these were combined and whether this varied across studies? Was a positive result defined as either marker being positive or both being positive? For example, Yamada (2019) reported the sensitivity and specificity of bombinin anti-3&#x02019;-sialyllactose IgG and CA-19 using predictive equations rather than a simple combination of the two tests. How was this handled in the analysis? The text provides data for calculating sensitivity based on a simple definition of positivity (resulting in a sensitivity of 93%, as in this review, with a positive result defined as either being positive), but there is no information to calculate the specificity of the combined screening using the same definition. Kashiro et al., on the other hand, appear to have combined two binary results (presumably defining positivity as either test being positive).</p><p>6. Please report the full results of the sensitivity analysis in the supplementary material. The manuscript states that sensitivity analyses did not show significant changes, yet the discussion mentions that "sensitivity analyses indicated heterogeneity might be associated with very large or small sample sizes." This seems inconsistent.</p><p>7. Exclusion criteria: Please clarify what is meant by "studies with excessive heterogeneity in design, patient population, biomarker detection method." How were these defined? Additionally, what threshold was used for defining "small-scale studies"?</p><p>8. Could you report how pancreatic cancer was excluded in each study?</p><p>9. The manuscript states as a strength that "advanced statistical models accommodated variability and calculated pooled estimates." This is too general. The analysis appears to use a standard random-effects meta-analysis. Please clarify.</p><p>10. The manuscript states that "most studies (n = 27) evaluated more than one biomarker," yet Table 2 reports only a single set of numbers per study. Please clarify this discrepancy.</p><p>11. The manuscript states that "all relevant data are within the manuscript and its Supporting Information files," but the numbers of TP, FP, FN, and TN needed to reproduce Figure 7 are missing. Please provide these.</p><p>12. In Table 2, what does "NC" stand for in the control group?</p><p>**********</p><p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link> ). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link> .</p><p>Reviewer #1:&#x000a0;No</p><p>Reviewer #2:&#x000a0;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#x000a0;<ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link> . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#x000a0;<email>figures@plos.org</email> . Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article article-type="author-comment" id="pone.0322720.r003"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322720.r003</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322720" id="rel-obj003" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">25 Mar 2025</named-content>
</p><p>Response to Editor</p><p>Dear Editor,</p><p>Thank you for the opportunity to revise our manuscript. We have carefully revised the manuscript in accordance with the reviewers' suggestions and adjusted the manuscript formatting to match the PLOS ONE template, ensuring it fully complies with the journal's style requirements.</p><p>All raw data necessary for reproducing our findings have been provided within the main manuscript and supplementary materials. Additionally, we have included the names of the data extractors (Line 153) and specified the date of data extraction (Line 140) in the main text. A comprehensive table showing the complete risk of bias and quality assessment for each included study is provided in the supplementary material (STable 3).</p><p>In response to the editorial requirements, we have also made the following additions to the supplementary files:</p><p>A numbered table of all studies identified through the literature search, including those excluded from the analyses along with the reasons for exclusion;</p><p>A complete table of all data extracted from the primary research sources for the systematic review and/or meta-analysis, including the names of data extractors, dates of extraction, and confirmation of study eligibility;</p><p>Moreover, an explanation of how missing data were handled has been incorporated into the manuscript (Lines 170&#x02013;174).</p><p>Furthermore, we have emphasized the urgent clinical need for early diagnosis of pancreatic cancer in the Introduction section (Lines 69-72) and highlighted the potential utility of numerous novel biomarkers for diagnosing pancreatic cancer at an early stage(Lines 86-94) .</p><p>We hope these revisions have sufficiently addressed the reviewers' concerns and improved the quality of our manuscript.</p><p>Thank you again for considering our manuscript for publication in PLOS ONE. We look forward to your favorable response.</p><p>Yours sincerely,</p><p>Yani Song</p><p>On behalf of all co-authors&#x02003;</p><p>Response to Reviewer #1</p><p>Dear Reviewer #1,</p><p>Thank you for your thorough review and valuable comments. We have carefully addressed each point you raised and implemented the suggested revisions to enhance the clarity, consistency, and presentation of our manuscript. Below, please find our point-by-point responses:</p><p>1. There are several inconsistencies in the font size and type in the manuscript. Check and fix them.</p><p>Response: We appreciate your observation. We have thoroughly reviewed the manuscript and corrected any inconsistencies in font size and type. These adjustments ensure a more uniform and professional appearance throughout the text.</p><p>2. When you reference a figure or table in the text, do not include the description of that figure or table.</p><p>Response: Thank you for the clarification. We have removed any descriptive text when referencing figures and tables in the main body of the manuscript. Only the figure or table number is now included.</p><p>3. Line 96-113: I think you could make a table for this or list the points in bullets to make it easier to read through.</p><p>Response: Thank you for this helpful suggestion. In response, we revised the content around lines 96&#x02013;113 by listing the key points in bullet format (lines 106&#x02013;124). We believe this revision improves readability and clarity for the reader.</p><p>4. Line 104: State the full form of QUADAS-2</p><p>Study selection: How did you access interrater reliability?</p><p>Response: We have now stated the full form of QUADAS-2(Line 114-115) and explained each of its domains in greater detail (Supplementary Tables 2 and 3). Additionally, we clarified how we applied this tool to assess risk of bias and applicability concerns in the included studies. We clarified that two independent reviewers assessed each study using the QUADAS-2 tool. Disagreements were resolved through discussion or consultation with a third reviewer. (lines 177&#x02013;186)</p><p>5. Line 147-149: What guided setting a benchmark score of 3 for inclusion?</p><p>Response: We have clarified the rationale for using a QUADAS-2 threshold. In our revised text (lines 177&#x02013;186), we explain that studies with high risk of bias in at most one domain (out of four bias domains) were included. The original reference to a &#x0201c;3-point&#x0201d; standard has been removed to avoid confusion. Instead, we specify that at least three domains of bias must not be rated as high risk for a study to be included.</p><p>6. Line 176: &#x0201c;Insufficient sample size&#x0201d; could be regarded as vague. What sample size was considered insufficient and why?</p><p>Response: We have replaced the phrase &#x0201c;insufficient sample size&#x0201d; with a clear cutoff of fewer than 30 participants (line 212-213). Studies with fewer than 30 participants were excluded due to concerns about statistical power and reliable estimation of diagnostic performance.</p><p>7. Line 181: &#x0201c;Tables 1 and Table2&#x0201d; fix the typo.</p><p>Response: We have corrected this typographical error in line 219.</p><p>8. Line 183-186: These sentences are confusing.</p><p>Response: We have revised the text in lines 221&#x02013;227. We now clearly distinguish between healthy control group (HC) and non-cancer control group(NC) including pancreatitis, benign pancreatic diseases in the included studies.</p><p>9. Line 211: Kindly list the major proteins identified in these studies.</p><p>Response: We have expanded Table 3 to include the specific protein biomarkers evaluated in each study (line 245). Each biomarker is now clearly listed, providing detailed insight into the diagnostic markers investigated.</p><p>10. Line 307: You can include the funnel plot for this finding.</p><p>Response: We have included a funnel plot (Fig 6.E) for the results related to potential publication bias (lines 370&#x02013;371). This funnel plot was generated using Deeks&#x02019; test (p = 0.04), and we note in the Discussion that any relevant findings should be interpreted with caution due to potential bias.</p><p>11. Line 296: Kindly list the major metabolites identified in these studies.</p><p>Response: As with the proteins, we have updated Table 3 to include all major metabolites reported in the relevant studies (line 245).</p><p>We sincerely appreciate your detailed review and constructive feedback. Your suggestions have significantly enhanced the clarity, coherence, and scientific rigor of our manuscript. We hope our revisions meet your expectations. Please let us know if there are any additional concerns or suggestions.</p><p>Kind regards,</p><p>Yani Song</p><p>On behalf of all co-authors</p><p>Response to Reviewer #2</p><p>Dear Reviewer #2,</p><p>Thank you for your thoughtful review and for recognizing the comprehensive scope of our work on early diagnostic biomarkers for pancreatic cancer. We value your insightful comments on the methodology and have addressed each point in detail below:</p><p>1. The authors pooled data by biomarker type. However, even within each type, there is variability in the specific biomarkers and their cut-off values. I am not a subject expert, but I wonder how meaningful it is to combine such different biomarkers.</p><p>Response: We sincerely appreciate the reviewer&#x02019;s insightful observation regarding the heterogeneity within biomarker categories. This is a critical consideration, and we acknowledge that pooling studies with distinct biomarkers and varying thresholds introduces potential limitations. Below, we clarify our rationale and address the validity of this approach:</p><p>(1). Rationale for Pooling by Biomarker Type</p><p>Our primary goal was to evaluate the overall diagnostic potential of broad biomarker categories (e.g., miRNAs, proteins) for early pancreatic cancer detection. While individual biomarkers within a category may differ mechanistically, grouping them by type allows us to:</p><p>(1.1). Assess the overall performance of biomarker categories (e.g., miRNAs vs. proteins), guiding future research priorities.</p><p>(1.2). Compare liquid biopsy-based biomarker classes (e.g., ctDNA vs. metabolites) to determine if they offer distinct advantages in sensitivity or specificity.</p><p>(1.3). Provide clinicians with actionable insights on which biomarker categories might complement existing diagnostic tools like CA19-9.</p><p>(2).Addressing Heterogeneity Within Categories</p><p>We agree that variability in biomarkers and their thresholds can affect pooled estimates. To mitigate this, We used a random-effects model, which accounts for heterogeneity by assuming true effect sizes vary across studies. Subgroup analyses were performed, such as separating studies using ELISA for protein biomarkers from those using mass spectrometry (Fig. 9). These analyses revealed no significant differences in performance, suggesting that methodological variability had limited impact. We explicitly reported high I&#x000b2; values (e.g., 83-98% for proteins and metabolites), emphasizing the need for cautious interpretation.</p><p>(3).Clinical and Biological Justification</p><p>Despite variability, biomarkers within a class often share biological relevance:</p><p>miRNAs: Many regulate overlapping oncogenic pathways and are consistently dysregulated in pancreatic cancer.</p><p>Proteins: While individual markers vary (e.g., S100P, MIC-1), they often reflect tumor-associated inflammation or immune evasion.</p><p>Metabolites: Altered lipid or amino acid profiles broadly indicate metabolic reprogramming, a hallmark of cancer.</p><p>Pooling these biomarkers provides a holistic view of their collective diagnostic utility, even if individual candidates require further validation.</p><p>(4).Limitations and Future Directions</p><p>We recognize the limitations of this approach and have revised the Discussion to emphasize:</p><p>The need for standardized biomarker panels: Future studies should prioritize validating specific combinations rather than isolated markers.</p><p>The importance of harmonizing thresholds: Cut-off values should be optimized in large cohorts to reduce variability. We acknowledge that individual biomarkers may exhibit different cut-off values, sensitivities, and specificities, which could limit the generalizability of pooled estimates.</p><p>While pooling biomarkers by category introduces heterogeneity, this approach aligns with the study&#x02019;s exploratory aim to compare broad diagnostic strategies. We agree that future research should focus on standardizing specific biomarker panels, and we thank the reviewer for raising this important point.</p><p>We further have emphasized this limitation in our Discussion. (Lines 527-538)</p><p>2. The authors state that studies with a QUADAS-2 score of 3 or higher were included. QUADAS-2 has four domains for bias and three for applicability. Could you clarify how the scoring was performed? Does a total score of 7 indicate inclusion, or was the focus only on bias? Since bias and applicability have different implications, combining them does not seem appropriate.</p><p>Response: We agree with your concern that combining bias and applicability domains is inappropriate. In our revised manuscript (lines 177&#x02013;186), we clarify that we did not merge these domains into a single score. Instead, we focused primarily on the four bias domains. Studies with at most one domain rated as high risk of bias in these four areas were included. We have removed references to a &#x0201c;3-point&#x0201d; system and now explain precisely how we assessed and reported each domain&#x02019;s outcome. The results are provided in Supplementary Table 3.</p><p>3. Please provide the QUADAS-2 assessment results for each study.</p><p>Response: We have now included the full QUADAS-2 evaluation for each study in Supplementary Table 3.</p><p>4. Please specify the search dates.</p><p>Response: We have added the exact date of our literature search (June 1, 2024) to the Methods section (line 140), ensuring greater transparency regarding our search strategy.</p><p>5. The authors report the combination of CA-19 and other biomarkers. Could you elaborate on how these were combined and whether this varied across studies? Was a positive result defined as either marker being positive or both being positive? For example, Yamada (2019) reported the sensitivity and specificity of bombinin anti-3&#x02019;-sialyllactose IgG and CA-19 using predictive equations rather than a simple combination of the two tests. How was this handled in the analysis? The text provides data for calculating sensitivity based on a simple definition of positivity (resulting in a sensitivity of 93%, as in this review, with a positive result defined as either being positive), but there is no information to calculate the specificity of the combined screening using the same definition. Kashiro et al., on the other hand, appear to have combined two binary results (presumably defining positivity as either test being positive).</p><p>Response: Thank you for raising this important issue. To address your concern, we have carefully re-reviewed and re-classified the included studies concerning the combined analysis of CA19-9 with other biomarkers. Based on the methods reported in these studies, we categorized the combined analyses into two approaches:</p><p>Either-positive principle:</p><p>In these studies, sensitivity was calculated such that if either CA19-9 or the novel biomarker was positive, the overall test was considered positive. Conversely, specificity was calculated by requiring both CA19-9 and the novel biomarker to be negative to classify a case as negative. In other words, this approach applied an &#x0201c;OR&#x0201d; principle for positivity and an &#x0201c;AND&#x0201d; principle for negativity.</p><p>Predictive modeling or machine-learning methods:</p><p>Another group of studies utilized regression equations, scoring systems, or machine-learning algorithms (such as logistic regression, multi-marker panels, or other algorithms) to estimate the sensitivity and specificity of combined testing. Typically, an integrated score or predicted probability was used as a threshold: results exceeding this threshold were classified as positive, while those below were classified as negative. Hence, sensitivity and specificity in these studies were not calculated by simple binary combinations but rather determined directly through predictive modeling or receiver operating characteristic (ROC) analysis.</p><p>For these studies, we first conducted an overall meta-analysis to estimate the diagnostic performance of biomarkers combined with CA19-9. Subsequently, subgroup analyses were conducted according to the different combination methods, and we assessed whether significant differences existed at the subgroup level.</p><p>Relevant methodological clarifications, along with the results obtained and their implications in the discussion, have been added to the manuscript.</p><p>We sincerely appreciate your highlighting this matter, which has greatly contributed to enhancing the clarity and rigor of our manuscript. Thank you again for your constructive feedback (Lines 396-431; Lines 490-504; Supplementary Figs 1 and 2).</p><p>6. Please report the full results of the sensitivity analysis in the supplementary material. The manuscript states that sensitivity analyses did not show significant changes, yet the discussion mentions that "sensitivity analyses indicated heterogeneity might be associated with very large or small sample sizes." This seems inconsistent.</p><p>Response: We have reviewed and consolidated our sensitivity analysis findings. All results, including leave-one-out analysis, have been added to the Supplementary Material (Supplementary Fig 7). We clarified that while small or large sample sizes could theoretically introduce heterogeneity, the actual sensitivity analyses did not reveal significant changes (lines 523&#x02013;524). We thank you for pointing out this discrepancy, which we have now resolved.</p><p>7. Exclusion criteria: Please clarify what is meant by "studies with excessive heterogeneity in design, patient population, biomarker detection method." How were these defined? Additionally, what threshold was used for defining "small-scale studies"?</p><p>Response: We have clarified that &#x0201c;excessive heterogeneity&#x0201d; refers to high risk of bias or inapplicability in multiple QUADAS-2 domains, leading to exclusion. Furthermore, we now explicitly define &#x0201c;small-scale studies&#x0201d; as those enrolling fewer than 30 participants, as they lack sufficient statistical power for reliable conclusions. (lines 121&#x02013;124)</p><p>8. Could you report how pancreatic cancer was excluded in each study?</p><p>Response: We have added a detailed explanation in the Methods section, clarifying how each included study ensured that enrolled participants in the control arm did not have pancreatic cancer. (lines 125&#x02013;137)</p><p>9.</p><supplementary-material id="pone.0322720.s006" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers.pdf</named-content></p></caption><media xlink:href="pone.0322720.s006.pdf"/></supplementary-material></body></sub-article><sub-article article-type="editor-report" id="pone.0322720.r004" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322720.r004</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Shuai</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Shuai Ren</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Shuai Ren</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322720" id="rel-obj004" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">26 Mar 2025</named-content>
</p><p>The Role of Novel Biomarkers in the Early Diagnosis of Pancreatic Cancer: A Systematic Review and Meta-Analysis</p><p>PONE-D-25-03633R1</p><p>Dear Dr. Song,</p><p>We&#x02019;re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#x02019;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#x02019;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#x000ae;</ext-link> &#x000a0;and clicking the &#x02018;Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#x02019;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>Kind regards,</p><p>Shuai Ren</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Congratulations to all the authors and thank you for addressing all comments and suggestions during the review process.</p><p>Reviewers' comments:</p></body></sub-article><sub-article article-type="editor-report" id="pone.0322720.r005" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322720.r005</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Shuai</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Shuai Ren</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Shuai Ren</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322720" id="rel-obj005" related-article-type="reviewed-article"/></front-stub><body><p>PONE-D-25-03633R1</p><p>PLOS ONE</p><p>Dear Dr. Song,</p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>You will receive further&#x000a0;instructions from the production team, including instructions on how to review your proof when it&#x000a0;is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.</p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>If we can help with anything else, please email us at customercare@plos.org.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access.</p><p>Kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Shuai Ren</p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article>